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Abstract  
 
Cancer is a hypernym used to describe a group of diseases characterised by the 
uninhibited growth and spread of abnormal cells in the body. An estimated 7.6 million 
annual deaths are attributed to the disease while 12.7 million new cases are reported 
every year. The severity of this  disease demonstrates the urgent requirement of novel 
anti-cancer therapeutic agents. The non-integrin laminin receptor, here designated the 
37 kDa/67 kDa laminin receptor (LRP/LR), is a multifunctional protein located on the 
surface, in the cytoplasm, in the perinuclear compartment and in the nucleus of cells. 
While this receptor is imperative for normal cellular functioning, it has also been 
implicated in many diseases – it serves as a cell surface receptor for numerous 
viruses, infectious prion proteins as well as certain respiratory tract pathogens. 
Additionally, LRP/LR has been found to have some involvement in zoonotic diseases 
and those involving neurodegeneration, such as Alzheimer’s disease. Most 
importantly for this study, LRP/LR has been implicated in cancer progression, where 
it was found to be overexpressed on the surface of various cancer cell lines, this 
overexpression correlating to increased metastasis. The aim of this study was to 
investigate the effect of the siRNA-mediated downregulation of LRP expression on 
the viability of tumorigenic lung and cervical cancer cells (A549 and HeLa, 
respectively). The cell surface LRP/LR and total LRP levels were investigated using 
flow cytometry and western blotting, respectively, in A549 and HeLa cells, the results 
revealing high percentages of both cell lines expressing LRP/LR on their surface. 
Additionally, A549 and HeLa cells express similar total levels LRP. The 
transfectability of these cells was confirmed and siRNA-LAMR1 was shown to 
significantly downregulate LRP expression (80% and 60% in A549 and HeLa cells, 
respectively). MTT assays revealed that the significant 13% and 18% reduction in 
cellular viability in A549 and HeLa cells, respectively, was as a consequence of LRP 
downregulation. This reduction in cellular viability was found to be a consequence of 
induced apoptosis (identified by the visualisation of the loss in nuclear integrity, as 
well as the significantly increased activity of the apoptosis-associated protein caspase-
3) and inhibited cellular proliferation in the aforementioned cells. These findings 
suggest that siRNA targeting LRP mRNA may act as a potential alternative 
therapeutic tool for the teatment of cancer.  
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1. CHAPTER 1 - INTRODUCTION 
 
1.1. Cancer 
 
Cancer is a hypernym used to describe a group of diseases characterised by the 
uninhibited growth and spread of abnormal cells in the body 1. If the growth of these 
cells is not restricted, death is often the result 2.  Cancer is an in discriminatory 
disease, however, diagnosis is directly proportional to age with the majority of cases 
occurring in the middle aged and older adults 2.  
 
Cancers are currently the global leading cause of mortality, accounting for 
approximately 7.6 million deaths (13% of all deaths) in 2008 3 while an estimated 
12.7 million new cancer cases were reported in the same year 4. One in every eight 
worldwide deaths is attributed to cancer 1 and in 2007 the disease caused more 
fatalities than AIDS, tuberculosis and malaria combined 1. The most commonly 
diagnosed cancers globally are lung, breast and colorectal cancers while the most 
common cause of cancer related deaths are lung, stomach and liver cancers 4.  
 
According to 2008 GLOBOCAN statistics, Southern Africa has the 7th highest cancer 
incidence rate, with breast cancer being the most common, followed by prostate, 
oesophageal and cervix uteri cancers (11%, 10%, 9% and 8% of all cases, 
respectively) (Figure 1.1). Among men (Figure 1.2a) in Southern Africa, prostate 
cancer is the most frequent, followed by lung cancer and oesophageal cancer, while in 
women (Figure 1.2b), breast cancer, cervix uteri cancer and oesophageal cancer are 
the most common 4.  
 
These statistics demonstrate the urgent requirement for the search and development of 
novel anti-cancer therapeutic agents. 
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Figure 1.1 – Global incidences of cancer. A map indicating the cancers of highest incidence with respect to country (adopted from 
GLOBOCAN 2008).     
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Figure 1.2 – Most frequently diagnosed gender specific cancer types in Southern Africa. Most frequent cancers among a) men and b) 
women in Southern Africa (adopted from GLOBOCAN 2008).   
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1.1.1. Cancer cause and prevention 
 
Numerous causes of cancer have to date been identified, both preventable and non-
preventable, all concerning malfunctioning genes and proteins involved in the control 
of cellular growth and division 2. The disease can be initiated by internal (inherited 
mutations, hormones, immune conditions and mutations occurring from metabolic 
processes) and external (tobacco, infectious organisms, chemicals and radiation) 
factors 2.  
 
Successful prevention of this disease has been observed by decreasing an individual’s 
exposure to certain external causative factors, such as cigarette smoking and 
excessive alcohol intake (30% of all cancer related deaths in the United States in 2011 
were expected to be caused by tobacco use) 2. Certain lifestyle choices are also of 
interest, as it is estimated that 33% of all cancer deaths in the United States in 2011 
were expected to be related to obesity, poor nutrition and physical inactivity, therefore 
also preventable 2. Additionally, approximately 2 million of the annually diagnosed 
cases of skin cancer could be prevented through adequate protection from the sun’s 
rays as well as the avoidance of indoor tanning 2.   
 
Certain cancers are caused by infectious agents such as viruses e.g. hepatitis B virus 
(HBV) 5; 6, human papillomavirus (HPV) 7; 8, human immunodeficiency virus (HIV) 9 
as well as bacteria such as Helicobacter pylori (H. pylori) 10; 11. These cancers can be 
prevented by vaccination 12, behavioural changes (for sexually transmitted diseases) 
or by antibiotics 2.     
 
1.1.2. Mechanisms of cancer progression   
 
Cells must attain a number of features in order to make the transition from being 
normal to becoming cancerous. These features, which are necessary in controlled 
measures for normal cellular development, homeostasis and survival, become 
exploited by cancerous cells, allowing them to propagate themselves with little 
impediment. Some of these features include the ability of cancer cells to grow in the 
absence of growth signals, their unresponsiveness to antigrowth signals, infinite 
! 5!
replicative potential, maintained angiogenesis, invasion and metastasis, and the 
evasion of apoptosis 13 (Figure 1.3). 
 
1.1.2.1. Cancer cells self-sufficiency in growth signals 
 
Mitogenic growth signals (GS) are required by normal cells for their progression from 
a quiescent to an actively proliferative state 13. The growth signals are transduced into 
the cell via specific transmembrane receptors, which bind ligands on the extracellular 
cell surface and subsequently relay the proliferative message along a signal pathway 
into the cell. It is not possible for normal cells to propagate in the absence of these 
growth signals; however cells that have become tumorigenic possess this ability 13. 
Tumour cells can also possess the ability to produce their own growth stimuli 
allowing them to proliferate without restriction 13.               
 
1.1.2.2. Cancer cells unresponsiveness to antigrowth signals 
 
Antigrowth signals, received by transmembrane receptors and subsequently integrated 
to intracellular signalling pathways, are present in normal cells, and are responsible 
for the prevention of cellular propagation as well as the maintenance of cellular 
quiescence and tissue homeostasis 13. In some cases, when forced out of the 
proliferative phase of the cell cycle by the action of antigrowth signals, cells maintain 
the ability to emerge from this state and proliferate in the presence of growth signals 
13. In contrast, antigrowth signals can also permanently prevent further cellular 
proliferation in certain cells e.g. cells which are fully differentiated 13. Normal cells 
are responsive to these signals due to cell cycle regulation; specifically the 
mechanism that assist in the passage of the cell through G1 (section 1.3 – the cell 
cycle). In normal cells, the decision to proliferate is governed by the retinoblastoma 
protein (pRb) – when hypophosphorylated, pRb blocks proliferation by requisitioning 
and altering E2F transcription factors, essential proteins involved in the transcription 
of genes which are required for the cells to progress through G1 13. It is essential for 
cancerous cells to become unresponsive to antigrowth signals if they are to flourish, 
therefore tumorigenic cells block the pRb pathway, liberating the E2F transcription 
factors, thus allowing for cellular proliferation 13. This disruption renders the cells 
insensitive to these antigrowth factors, therefore promoting tumour formation 13.        
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1.1.2.3. Cancer cells infinite replicative potential  
 
In 1997, Hayflick demonstrated that normal cells have a limited replicative potential, 
showing that the proliferation of cells in culture is finite 14 and once these cellular 
populations have attained their set number of proliferative steps, they become 
senescent (their propagation is discontinued) 13. It was shown that senescence could 
be avoided by disrupting the tumour suppressor proteins pRb and p53, enabling the 
cells to continue their multiplication, a step known as immortalisation 15. The 
replicative potential of normal cells is governed by telomeres (the ends of 
chromosomal DNA which become 50-100 bp shorter with every replicative cycle due 
to the inability of DNA polymerases to fully replicate their 3’ ends) 16. In almost all 
types of cancerous cells, telomere maintenance is observed 17, where the cells have an 
upregulated expression of telomerase (functions in the addition of hexonucleotide 
repeats onto the ends of telomeric DNA), thus allowing the telomeres to counteract 
their erosion 18. Evidence for tumour cells possessing an infinite replicative potential 
is gained from the observation that most cancer types propagated in culture appear to 
be immortalised 14.    
 
1.1.2.4. Cancer cells maintain angiogenesis 
 
Cellular functionality and survival is dependent on the adequate receipt of oxygen and 
nutrients, factors that are transported in the body by the vascular system. The 
importance of this process is further demonstrated by the observation that all cells and 
tissue are found to reside within 100 µm of a capillary blood vessels 13.    
 
Angiogenesis, a term used to describe the production of new blood vessels in the 
body, holds high importance in early organ development, however, once tissue 
formation has been completed, this process is both transitory and tightly regulated 13. 
Since cancerous cells have increased cellular proliferation, they require higher 
concentrations of oxygen and nutrients; this is achieved through the initiation of 
tumour angiogenesis by the cells, a step necessary for their maintained growth 19.  
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Figure 1.3 – The six main hallmarks of cancer. The six main mechanisms 
by which cells become cancerous (adopted from 13). 
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1.1.2.5. Cancer cells invasion and metastasis  
 
In the developmental process of most human cancers, cells are able to secede from the 
primary tumour site and invade adjacent tissues where it is possible for them to 
establish new colonies 13, a progression termed metastasis. This process allows cancer 
cells to inhabit new areas of the body where initially there is little spatial constraint 
and nutritional restriction 13. Metastasis has been found to be the cause of 90% of all 
human cancer deaths 20, as it is often difficult to inhibit the spread of these cells.  
 
The molecular mechanisms of invasion and metastasis have been investigated and a 
number of influential proteins have been identified, with several involved in the 
tethering of cells to their surrounding environment. These proteins become altered in 
tumours exhibiting invasive or metastatic tendencies 13. Some such proteins include 
the cell-cell adhesion molecules (CAMs)13, extracellular proteases 21; 22 and the 
cadherin 23 and integrin 24; 25 families.   
 
1.1.2.6. Cancer cells evasion of apoptosis 
 
Tumour cells expand by increased proliferation and maintain this by a decreased level 
of cell death. Apoptosis is a form of programmed cell death that is essential for 
homeostasis, the elimination of cells during development and the eradication of cells 
possessing harmful mutations 26. The acquired resistance of cancerous cells to this 
process was first observed in 1972 by Kerr et al. – subsequent to hormone elimination 
from hormone-dependent tumours, substantial cell death was observed 27. Apoptosis 
is a tightly regulated process, with a number of triggers and pathways; a detailed 
description of this form of cell death will be outlined in the section to follow. It is 
increasingly being observed that the evasion of apoptosis is a hallmark noticed in 
most if not all cancer types 13, therefore targeting this process could be a possible 
therapeutic for the treatment of this disease. However, it must be noted that the 
evasion of apoptosis can be effectuated through the mutation or dysregulation of a 
number of proteins and/or genes, e.g. bcl-2 28; 29, p53 30, myc 31, adding to the 
complexity of targeting this process.  
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1.2. Apoptosis 
 
Apoptosis or programmed cell death is a physiological form of cell death which 
involves a cell actively committing suicide 32.  Apoptosis is a fundamental element for 
many cellular processes including normal cell turnover, which is important for 
homeostasis, proper development and the functioning of the immune system, 
hormone-dependent atrophy, embryonic development and chemical-induced cell 
death 26. Tissue damage occurs in cases where cells undergo too much apoptosis and 
this event is observed in medical conditions such as strokes and neurodegenerative 
disorders such as Alzheimer’s, Huntington’s and Parkinson’s diseases 26. In cases 
where cells evade apoptosis, medical conditions such as cancers may evolve 26.  Due 
to the consequences of the activation of this process, it is both stringently controlled 
and well regulated in the cell 33, with a large number of regulatory and effector 
proteins involved in the initiation and execution of the apoptotic pathways.  
 
1.2.1. Apoptotic pathways 
 
The process of apoptosis involves a number of proteins all implicated in intricate and 
cross-linked pathways. These proteins function in activation cascades, which increase 
the regulation of this form of cell death. The process of apoptosis takes place in the 
cell via two major pathways namely the death receptor (extrinsic) pathway and the 
mitochondrial-dependent (intrinsic) pathway (Figure 1.4). These two apoptosis-
inducing pathways can be triggered by a number of signals arising either extra- or 
intracellulary 34. 
 
1.2.1.1. Death receptor (extrinsic) pathway 
 
The death receptor pathway (Figure 1.4) is mediated by the activation of cell surface 
receptors known as death receptors. Death receptors belong to the tumour necrosis 
factor receptor (TNFR) gene super family, including TNFR-1, Fas/CD95, and the 
TRAIL receptors DR-4 and DR-5 35. These receptors span the membrane, and once an 
appropriate ligand has bound to them, transmit the apoptotic signals from the 
extracellular space into the cytoplasm of the cell 26. The binding of the ligand to the 
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cell surface receptor/death receptor results in the exposure of a conserved amino acid 
sequence, known as the death domain (DD), on the receptor to the cytosolic side of 
the plasma membrane 36. This results in the recruitment of adaptor molecules such as 
the Fas-associated protein with death domain (FADD) via DD-DD interactions. 
Furthermore, FADD also consists of a death effector domain (DED) which is 
involved in the recruitment and binding of procaspase-8 via DED-DED interactions 
36. The binding of the FADD to the receptor death domains forms the death inducing 
signalling complex (DISC), and when concentrated at the DISC, procaspase-8 possess 
the ability to undergo autocatalytic cleavage and activation, resulting in the 
production of active caspase-8 26. Active caspase-8 is then able to cleave inactive 
procaspase-3 forming active caspase-3, which then cleaves specific substrates, 
ultimately resulting in the death of the cell.  
 
Where the apoptotic signals generated by the activation of the death receptor is not 
sufficient to activate caspase-8 which in turn will activate caspase-3 via the death 
receptor pathway, the activated caspase-8 cleaves Bid (a member of the Bcl-2 family 
of proteins) to truncated Bid (tBid). tBid then activates the mitochondrial-dependent 
(intrinsic) apoptotic pathway as described below 33.    
 
1.2.1.2. Mitochondrial-dependent (intrinsic) pathway 
 
The mitochondrial-dependent apoptotic pathway (Figure 1.4) can be initiated by 
apoptotic signals from the death receptor pathway (described above) as well as death 
signals that originate inside the cell 37. The death signals originating inside the cell 
include damage to the DNA, oxidative stress, lack of nutrients, as well as 
chemotherapeutic drugs 26.  The aforementioned intracellular death signals cause a 
shift in the ratio of pro-apoptotic and anti-apoptotic proteins, which subsequently 
leads to an increase in the permeability of the outer mitochondrial membrane 38. The 
increase of the membrane permeability allows for the release of many pro-apoptotic 
proteins such as cytochrome c from the mitochondria to the cytosol 39. Once in the 
cytosol, cytochrome c binds to a monomeric molecule called Apaf-1, which then 
undergoes an ATP-dependent conformational change and oligomerisation, leading to 
recruitment of procaspase-9 and the formation of the apoptosome. In the apoptosome, 
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procaspase-9 is cleaved to active caspase-9, which in turn cleaves procaspase-3 to 
active caspase-3. Active caspase-3 is involved in the initiation of downstream events, 
e.g. DNA degradation, which ultimately results in the death of the cell 26.  
 
The degradation of DNA is accomplished through the action of the Caspase-Activated 
DNase (CAD), however, this endonuclease is found complexed to an inhibitor, 
Inhibitor of Caspase-Activated DNase (ICAD) and is therefore inactive 26. In 
apoptotic cells, active caspase-3 cleaves ICAD, releasing CAD, which then degrades 
DNA, causing cell death 26.      
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Figure 1.4 – The two main apoptotic pathways in mammalian cells. The death 
receptor (extrinsic) pathway receives a signal from the exterior of the cell e.g. binding 
of a ligand to the CD95L receptor, which activates the apoptotic pathway. The 
binding of a ligand to this death receptor recruits adaptor molecules and procaspase-8. 
Procaspase-8 is cleaved to form active caspase-8, which in turn cleaves procaspase-3 
activating it to caspase-3. The mitochondrial-dependent apoptotic (intrinsic) pathway 
is activated by intracellular signals e.g. damaged DNA, stress, lack of nutrients, 
chemotherapeutic drugs etc. These signals cause a change in the permeability of the 
mitochondrial membrane causing the release of cytochrome c from the mitochondrion 
into the cytosol. In the cytosol, cytochrome c interacts with Apaf-1 to form the 
apoptosome. The apoptosome is able to activate procaspase-9 to caspase-9, which in 
turn activates caspase-3. The intrinsic and extrinsic apoptotic pathways both converge 
at the activation of caspase-3 which then mediates the downstream pathways 
responsible for the biochemical and morphological changes observed in apoptotic 
cells (adopted from 36). 
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1.2.2. Cellular alterations resulting from apoptosis 
 
Once cellular initiation of programmed cell death pathways has occurred, 
morphological and biochemical changes in the cell become apparent.  
 
1.2.2.1. Morphological features of apoptosis  
 
At the onset of apoptosis, cellular and nuclear shrinkage is observed. Additionally, the 
chromatin undergoes condensation, forming sharply defined masses on the periphery 
of the nuclear membrane 40. The nucleus then becomes increasingly condensed in a 
process known as karyorrhexis and the cell detaches both from the surrounding tissue 
and the outer membrane, becoming convoluted and forming extensions 40. These 
extensions, called membrane blebs, then detach and form separate membranes 
surrounding cellular material, and are termed apoptotic bodies 40. The apoptotic 
bodies become phagocytosed into the surrounding cells and are ultimately degraded 
(Figure 1.5).  
 
The abovementioned process occurs exclusive of inflammation, which would be 
resultant from the release of intracellular contents into surrounding tissues 40. 
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Figure 1.5 – The morphological features associated with apoptosis in the cell. 
Once apoptosis has been initiated, the cell shrinks and the chromatin becomes 
condensed. The nucleus then constricts and collapses, following which the outer 
membrane of the cell looses its rigidity, becoming convoluted and forming 
extensions. The extensions, known as apoptotic bodies, surround cellular material and 
detach from the cell (adopted from http://cancerbattlefield.com/research/apoptosis/).  
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1.2.2.2. Biochemical features of apoptosis 
  
In addition to the abovementioned cellular morphological changes associated with 
apoptosis, certain biochemical alterations are also observed in apoptotic cells. 
 
The degradation of DNA is an imperative biochemical alteration occurring when cells 
undergo apoptosis. This process is mediated by the activity of endogenous DNases 
(e.g. Caspase-Activated DNase), which restrict double-stranded DNA 
internucleosomally, resulting in 180-200 bp fragments 41 which contain both blunt 
ends 42 as well as single base 3’ overhangs 43.   
 
1.2.3. Caspases and apoptosis  
 
Cysteine-dependent aspartate-specific proteases, commonly referred to as caspases, 
are a family of proteins that have little association with nonspecific degradative 
processes, rather, they are involved in specific signalling cascades 44. They are 
enzymatically active and show specificity toward protein substrates containing 
aspartate, using their cysteine side chain to catalyse the cleavage of the peptide bond 
45; 46. 
 
The physiological functions of the caspases have predominantly been determined by 
genetic mouse knockout studies which indicate that these proteins have numerous 
functions in the cell, including involvement in the regulation of cellular proliferation 
47, differentiation 47, migration 47 and the bodies innate immunity 48. While caspases 
are associated with the aforementioned processes, they are fundamental in the 
regulation of apoptosis.  
   
Caspases are identified and grouped according to function; those associated with 
innate immunity (group I) and those involved in the regulation of apoptosis (group II) 
48. Group II/apoptosis associated caspases are further divided into two groups, namely 
initiator/apical (caspase-2, -8, -9 and -10) and effector/executioner (caspase-3, -6 and 
-7) caspases 48. Initiator caspases are produced as ineffective zymogens and require 
the formation of multicomponent complexes, which trigger their dimerisation, to 
become active 49. Effector caspases are also produced as ineffective zymogens, and 
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become functional through activated initiator caspase-mediated proteolytic processing 
48.   
 
In multicellular organisms, it is imperative for an appropriate balance between 
cellular proliferation and death to be maintained 47. Because of the fundamental role 
of apoptosis in the elimination of damaged cells, aberrant expression of the caspases 
(either in excess or inhibited) holds implications in a number of pathological 
conditions, ranging from autoimmune diseases, sepsis, immunodeficiency, 
neurodegenerative disorders and cancer 47.    
 
The evasion of apoptosis is a well known hallmark of cancer 13 (discussed in section 
1.1.2.6), and an overwhelming amount of experimental evidence has suggested that 
active group II caspases play a fundamental role in bringing about the morphological 
and biochemical alterations associated with this form of cell death (discussed in 
sections 1.2.2.1 and 1.2.2.2, respectively) 40. The process is not fully elucidated, 
however, it is known that the effector caspase-mediated cleavage of a number of 
target proteins (Table 1.1) involved in the maintenance of cellular structure 50 is partly 
responsible. 
 
Since caspases are so essential in the execution of apoptosis, the study of their 
activation for the determination of the presence of apoptotic cells could therefore be 
advantageous for the establishment of the efficacy of potential cancer therapies.    
 
 
 
 
 
 
 
 
 
 
 
 
! 17!
 
 
 
 
Table 1.1 – Apoptotic morphology associated proteins cleaved by caspases  
 
Protein Function/Localisation 
Actin 
Microfilament forming protein with various localisations and 
functions, i.e. regulation of cell shape in the cortical cytoskeleton 51; 
52; 53 
Spectrin / fodrin Actin cross-linking protein in cortical cytoskeleton 54; 55; 56 
Beta-catenin Intracellular attachment protein in cell-to-cell junction sites 57 
Gelsolin Microfilament protein 58 
Gas2 Microfilament organising protein 59 
PAK2 Protein kinase involved in cytoskeleton regulation 60 
MEKK-1 Regulation of cell survival at the cell-matrix and cell-cell contacts 61 
FAK Regulation of cell adhesion at cell-matrix and cell-cell contacts 62 
Keratins 18 & 19 Intermediate filament protein in keratinocytes 63 
Rabaptin 5 Membrane protein that regulates intracellular vesicle traffic 64 
Lamin A and B Intermediate filament that forms the nuclear lamina 65; 66 
NuMa Mediator of nuclear chromatin-matrix protein interactions 67 
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1.3. The cell cycle 
 
The cell cycle is a term referring to the highly regulated process by which a cell 
grows 68, undergoes duplication 69 and accurately replicates, transferring its genetic 
information to daughter cells 69. This progression is divided into 5 major phases 
(Figure 1.6), namely gap 0 (G0), gap 1 (G1), gap 2 (G2), mitosis (M phase) and DNA 
synthesis (S phase), each tightly regulated through the action of a number of proteins 
69. 
 
A cell is referred to as quiescent or senescent in G0 when it is either temporarily or 
permanently excluded from the cell cycle, respectively. Cells temporarily in G0 enter 
G1 in response to extracellular signals such as growth factors and mitogens, and after 
entering this stage, proceed to S phase where DNA replication occurs in preparation 
for mitosis 69. G2 phase involves the rapid growth of the cell and protein synthesis in 
preparation for M phase, the final step in the cell cycle. M phase is an intricate and 
multi-step process involving the generation of mitotic spindles, sister chromatid 
segregation and cell division 69, which ultimately results in the formation of two 
identical daughter cells. 
 
The progress of the cell through the cell cycle must be stringently controlled to ensure 
that the initiation of each of the aforementioned phases occurs only once the 
preceding phase has adequately reached its completion, consequently, a number of 
cell cycle checkpoints exist 69. This refers to the monitoring of critical cell cycle 
events e.g. DNA replication, and in response to possible errors in these processes, the 
progression of the cell through the cell cycle is halted while the error is fixed, if this 
error is irreparable, the death of the cell is induced 70. 
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Figure 1.6 – The cell cycle. The cell cycle is divided into 5 phases; G0 – where cells 
are temporarily or permanently excluded from the cell cycle, G1 – cells enter this 
phase from G0 in response to growth signals, S – the replication of DNA, G2 – a phase 
of rapid growth and protein synthesis in preparation for M phase, M – the generation 
of mitotic spindles, sister chromatid segregation and cell division.  (Image adopted 
from http://www.ch.ic.ac.uk/local/projects/s_liu/Html/Introduction.html). 
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In some cases, excessive expression of growth factors and mitogens, which propel the 
cell out of G0 (as discussed above), leads to the unnecessary progression of the cell 
through the cell cycle, generating a mass of non-functional cells. Damaged or mutated 
cells allowed to bypass cell cycle checkpoints pose a serious problem, as these 
mutations often permit aberrant cellular proliferation and insensitivity to death signals 
70. These enlightenments reveal the importance of the correct regulation of the cell 
cycle in disease progression, especially with respect to cancer.  
 
1.4. The 37-kDa/67-kDa laminin receptor precursor/laminin receptor 
 
Laminins belong to a large family of extracellular matrix proteins that are involved in 
a number of biologically significant processes, including cellular differentiation, 
migration, adhesion, growth and signalling 71. The effects of these proteins are often 
mediated through their interaction with integrin and non-integrin laminin-binding 
proteins, which function as receptors in the linkage of laminin in the extracellular 
matrix to intracellular signalling cascades 71.  
 
A major laminin binding partner is the multifunctional protein, designated in this 
study, as the 37-kDa/67-kDa laminin receptor precursor/laminin receptor (LRP/LR). 
This receptor has been variously labelled as the 37/67-kDa high affinity laminin 
receptor protein 72, the 37-kDa laminin-binding protein (37LBP) 73, the laminin 
receptor precursor (LRP) 72, the 67-kDa laminin receptor (67LR) 74, laminin receptor 
(LAMR) 75, laminin-binding protein precursor p40 (LBP-p40) 72 and the ribosomal 
protein SA (RPSA) 76.  
 
1.4.1. Structure of LRP/LR 
 
The gene encoding LRP/LR consists of seven exons, six of which correspond to the 
coding sequence 77, however, it contains no signal sequences directing the protein to 
its various cellular locations, e.g. the nucleus or the cell membrane 78; 79. The crystal 
structure of this protein was solved at 2.15 Å resolution 80, and was found to consist 
of 295 amino acid residues, with a theoretical molecular mass of 32854 Da 77. In 
immunoblots of cellular extracts, however, LRP and LR appear at molecular weights 
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of 37 and 67 kDa, respectively, showing dissimilarity to the theoretical molecular 
weight 77.   
 
The 67 kDa laminin receptor may be formed from the 37 kDa laminin receptor 
precursor 81; 82, with the exact mechanism of this conversion currently still elusive. 
However, some studies have suggested that the unglycosylated 37 kDa form becomes 
acylated at Ser2 through the action of fatty acids; and this acylation is a critical step in 
the conversion of the 37 kDa form to the 67 kDa form 83; 84.  
 
LRP/LR is divided into two main domains, namely the N-terminal (aa 1-209) and C-
terminal (aa 210-295) domains 77.  It belongs to a family of type II membrane 
proteins, which span the plasma membrane once (between amino acids 86-101), with 
its N-terminus found on the cytoplasmic side of the cell membrane and its C-terminus 
exposed to the extracellular space 85.  It has also been found to possess binding sites 
for laminin (aa 161-180 and aa 205-229), however these sites are not exclusive to 
laminin binding; the 161-180 amino acid laminin binding sequence is also able to 
bind Heparin, while PrP binds to the 205-229 sequence in addition to laminin 86; 87 
(Figure 1.7).    
 
 
 
 
 
 
Figure 1.7 – Structure of LRP/LR. LRP/LR is a 295 aa transmembrane protein. It 
has a cytoplasmic N-terminus and an extracellular C-terminus. It contains binding 
sites for laminin, PrP and Heparin.  
! 22!
1.4.2. Cellular locations and physiological roles 
 
LRP/LR has been discovered in numerous cellular locations; it is found localised in 
the cytoplasm 8; 75; 88, in the cell membrane on the cell surface 89, in the perinuclear 
compartment 75; 90; 91 and in the nucleus 90; 91.  
 
In the cytoplasm, LRP/LR (in the form LBP-p40) has been found to be involved in 
protein synthesis 88 and the maturation of the 40S ribosomal subunit 88. It also 
interacts with the 18S rRNA and the ribosomal protein S21, playing a role in the 
maturation and assembly of the ribosome 76; 88; 92; 93; 94. On the cell surface, it acts as a 
membrane receptor for ECM components such as laminin-1, carbohydrates and 
elastin 95 as well as certain growth factors e.g. Midkine 96; 97; 98; 99. This protein is 
reported to interact with prion proteins in the perinuclear compartment 100 and in the 
nucleus, it is associated with DNA and some histones 90, functioning as a constituent 
of the nuclear machinery 94; 98; 101.  
 
In addition to the abovementioned physiological roles of LRP/LR, this receptor is also 
imperative in a variety of cellular processes required for normal functionality and 
homeostasis, namely cellular proliferation/growth 86, migration 102, invasion 103, 
angiogenesis 104, extracellular remodelling 105 and differentiation 106, further 
demonstrating its importance.       
 
1.4.3. Pathological implications of LRP/LR 
 
While LRP/LR is imperatively functional in a number of physiological and 
homeostasis related processes, it has also been implicated in many diseases. LRP/LR 
serves as a cell surface receptor for numerous viruses (Dengue virus stereotypes 1, 2 
and 3 107, Sindbis virus 108; 109, Venezuelan Equine Encephalitis Virus 110 and Adeno-
Associated Virus serotype 2, 3, 8 and 9 111), infectious prion proteins 112,  as well as 
the respiratory tract pathogens Streptococcus pneumoniae, Neisseria meningitidis, and 
Haemophilus influenzae, the causative agents of meningitis 113. LRP/LR has also been 
found to have some involvement in zoonotic diseases 85 and those involving 
neurodegeneration, such as Alzheimer’s disease 85. Additionally, this receptor is 
suggested to regulate microgliosis 114 and function in the binding of inflammatory 
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macrophages to the basement membrane 115, both of which can contribute to 
pathological conditions. Furthermore, a number of studies have implicated this 
protein in cancer progression. 
 
1.4.3.1. LRP/LR and its role in cancer and metastasis 
 
The pathological implications of LRP/LR are further observed in cancer, where the 
overexpression of this protein is detected in several cancerous tissues (Table 1.2). An 
increased level of this protein on the cell surface has been shown to correlate with the 
aggressiveness of the cancer 74 as well as malignancy 116; 117.  
 
 
 
Table 1.2 – Cancer types overexpressing LRP/LR 
 
Human tumours overexpressing LRR/LR Reference 
Colon cancer 118 
Cervical preneoplastic & neoplastic  
squamous epithelial lesions 
119
 
Breast carcinoma 120; 121 
Uterine adenocarcinoma 122 
Colorectal carcinoma 123 
Gastric adenocarcinoma 124 
Prostate cancer 125 
Laryngeal squamous carcinoma 126 
Small cell lung cancer 127 
Acute myeloid leukaemia 128 
Ovarian carcinoma 116 
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A possible role of LRP/LR in cancer was first reported by Rao et al. in 1983 where 
the 67 kDa laminin receptor was purified from BL6 murine melanoma cells 96. It was 
suggested in this study that the laminin receptor may play a role in the interaction of 
metastasising tumour cells with the basement membrane  96. An imperative step in 
cancer metastasis is the erosion of the basal lamina by primary tumour cells, allowing 
them to enter and travel through the bloodstream, and form secondary tumours 
elsewhere in the body (Figure 1.8). LRP/LR plays an important role in this process, 
owing to its interaction with the cell adhesion molecule laminin-1 85. This interaction 
induces laminin-1 mediated basement membrane attachment in conjunction with the 
local degradation of the basal lamina, permitting cell movement 85. It has been 
demonstrated that blocking cell surface LRP/LR with anti-LRP/LR specific antibodies 
significantly deceases the invasive potential of cancerous cells 85; 129; 130; 131; 132, 
providing further evidence for the role of this receptor in cancer metastasis. 
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Figure 1.8 – The process of tumour metastasis. Tumour metastasis involves the 
erosion of cancerous cells through the basal lamina and their subsequent entrance into 
the blood stream. The cells travel through the blood stream, adhere to and penetrate 
the wall of the capillary and finally establish secondary tumours (adopted from 
http://www.utm.utoronto.ca/~w3bio315/picts/lectures/lecture20/).   
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1.4.3.2. LRP/LR and its role in cancer angiogenesis 
 
The angiogenic process (the formation of blood vessels) is imperative for the growth 
of cancerous tumours, and LRP/LR is further implicated in this process through its 
interaction with the extracellular molecule laminin-1 133. An imperative step in the 
angiogenic process is the formation of tubular structures; this requires the action of 
certain cell surface receptors, which recognise extracellular matrix proteins and 
mediate cell adhesion 133, since LRP/LR is involved in mediating these processes, its 
role in angiogenesis is likely. It was observed that the interaction between the 67 kDa 
LR and the β-chain of laminin is implicated in the formation of tubes in the 
angiogenic process 134 as well as being functional in later aspects of this process 133. 
Additionally, a study undertaken in our lab discovered that blocking cell surface 
LRP/LR with the anti-LRP specific antibody, W3, completely destroyed angiogenic 
tube formation in HUVECs (Human umbilical vein endothelial cells) 135. These 
findings implicate LRP/LR in the angiogenic process.    
 
1.4.3.3. LRP/LR and cellular viability 
 
The human laminin receptor gene sequence has homologues in a number of 
organisms 75 and the protein sequence shares structural homology with Archaea 80. 
This conservation of LRP/LR gene and protein homology indicates that it is an 
essential molecule, involved in basic cellular functionality 75. Yeast homologues of 
LRP/LR have been found to be essential for cellular viability 136, where it functions in 
the processing of the 20S-18S rRNA as well as ribosome assembly 137. Additionally, 
LRP/LR has been found to be associated with the ribosome in mouse 88 and plant 138 
models, indicating a role of the receptor in cellular viability in these organisms. In 
humans, the laminin receptor’s importance in cellular viability is found in its 
localisation to the nucleus where it has been implicated in pathways involving cell 
signalling 117. In addition to nuclear localisation, certain extraribosomal functions 
associated with the C-terminus of the human laminin receptor is also suggested  to 
alternatively regulate cellular viability 75.  
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Since LRP/LR holds much importance in the maintenance of cellular viability, the 
dysregulation of this protein may cause aberrant cell survival, and therefore, targeting 
this protein could be beneficial for disease treatment.   
 
1.4.3.4. LRP/LR and the evasion of apoptosis 
 
LRP/LR has been implicated in the blockage of the apoptotic process 72. siRNA-
mediated downregulation of LRP/LR stimulated the induction of apoptosis in Hep3B 
(transformed liver) cells, detected by Annexin V/propidium iodide staining as well as 
by double staining with Annexin V and an antibody directed against the 37/67 kDa 
laminin receptor 72. Furthermore, the reduction of LRP/LR expression in HeLa cells 
also resulted in apoptosis 139. These results suggest that the 37/67 kDa LRP/LR plays 
a fundamental role in preventing the apoptotic form of cell death in these cells, and 
therefore could be a potential target for the treatment of cancers displaying increased 
expressions of this receptor.  
 
1.4.3.5. LRP/LR and cellular proliferation 
 
Recent evidence has implicated this protein in the progress of the cell through the cell 
cycle, where the reduction of LRP/LR expression in HT1080, HeLa and HepG2 cells 
resulted in G1-phase cell cycle arrest through the alteration of the expression of cell 
cycle regulatory proteins 140.  
 
Taking into account that the progression of the cell through the cell cycle allows for 
cellular proliferation (an important hallmark of cancer), and that LRP/LR can be 
implicated in the dysregulation of this process, targeting this receptor could be 
advantageous for the treatment of this disease.  
 
1.5. RNA silencing 
 
RNA silencing refers to a regulatory mechanism which functions in either suppressing 
transcription (known as transcriptional gene silencing [TGS]), or activating sequence-
specific RNA degradative processes (known as posttranscriptional gene silencing 
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[PTGS] or RNA interference [RNAi]) 141. This mechanism was initially reported in 
plants, however, following this discovery, PTGS/RNAi has been reported in almost 
all eukaryotic organisms including protozoa 142, flies 143, nematodes 144, insects 145, 
parasites 146 as well as mouse 147 and human 148 cell lines. The main components in 
PTGS/RNAi are the double-stranded RNA (dsRNA) molecules which act as inducers 
and activators of these processes through their cleavage of inducer molecules, which 
cause the destruction of cellular or viral mRNA molecules 141. 
 
1.5.1. Components of gene silencing 
 
Dicer and the RNA-Induced Signalling Complex (RISC) are enzyme complexes that 
play integral roles in PTGS/RNAi. Dicer is involved in PTGS/RNAi initiation, while 
RISC functions in targeting and degrading the mRNA 149.  
 
1.5.1.1. Dicer 
 
Dicer is a member of the RNase III family of proteins which are nucleases that 
demonstrate specificity for dsRNA 150. It contains four distinct domains: an amino 
terminal helicase domain, dual RNase III motifs, a dsRNA binding domain and a PAZ 
domain 151; 152. Dicer possesses the ability to digest dsRNA, forming uniform small 
sized RNA molecules called small interfering RNA (siRNA) of approximately 22 bp 
141. Complete digestion of the dsRNA using RNase III nucleases results in fragments 
ranging from 12-15 bp 153. This is due to the RNase III enzyme acting as a dimer, 
therefore digesting the dsRNA with the aid of two catalytic centres 141. A model for 
the digestion of dsRNA to siRNA by Dicer suggests that this enzyme folds on the 
dsRNA substrate producing four sites for catalysis 154. This results in the two terminal 
sites, which have maximum homology with the RNase III catalytic sequence, 
remaining active while the other two sites which contain partial homology lose their 
functional significance 154. The dsRNA processed by Dicer is therefore double in size 
when compared to the fragments produced by the other RNase III enzymes 154. 
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1.5.1.2. RNA-Induced Silencing Complex 
 
A study by Hammond et al. 143 demonstrated that targeting exogenous genes of 
Drosophila S2 cells in a sequence specific manner could be accomplished by the 
transfection of these cells with dsRNA. In this study, the inability of nuclease treated 
cellular extracts to degrade the associated mRNA, and the lack of this outcome with 
DNase I treatment established that RNA was an indispensable constituent of the 
nuclease activity 143. The sequence-specific nuclease activity observed in these 
cellular extracts responsible for the degradation of target mRNA was termed the 
RNA-induced silencing complex (RISC) 143. The RISC enzymatic complex consists 
of Argonaute (Ago), fragile X-related (FXR) and Tudor-Staphylococcus nuclease 
(Tudor SN) domain proteins 149.     
 
1.5.2. Mechanism of RNA interference 
 
Many aspects of this pathway remain elusive, however, various in vivo and in vitro 
experimental results have been combined to propose a mechanism for the 
PTGS/RNAi pathway 141. This pathway has been simplified into three basic steps:  
Step 1 is referred to as the initiation step and involves the binding of the RNA III 
nuclease Dicer to dsRNA, cleaving it into 21-25 nucleotide RNA fragments called 
siRNA 141 (Figure 1.9a).  
Step 2 is known as the effector step. The siRNAs are joined to a multinuclease 
complex known as RISC 141 (Figure 1.9b). The organization of siRNA (double-
stranded duplexes with two-nucleotide 3’ overhangs and 5’-phosphate termini) is 
essential for the incorporation of these molecules into the RISC complexes 155; 156 by 
the dsRNA-binding protein R2D2 157. RISC zymogens become enzymatically active 
upon the addition of ATP and the unwinding of the double stranded siRNA, resulting 
in only the most stable strand of siRNA remaining attached to RISC 154.     
Step 3 involves the silencing of the gene 141 (Figure 1.9c). The activated RISC is then 
able to cleave the target mRNA 158, identified by Watson-Crick base-pairing, with the 
single siRNA strand bound to the complex 143. The degradation of the target mRNA 
has been suggested to be endonucleolytic 159 and occurs at the central point of the 
region complementary to the siRNA, ten nucleotides upstream of the nucleotide 
paired with the 5’ end of the guide siRNA 160. The cleavage process is not ATP-
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dependent 161, however, several repetitions of mRNA cleavage requiring the release of 
cleaved products are more efficient in the presence of ATP 143.    
 
 
 
 
 
Figure 1.9 – The mechanism of RNA interference. a) The pathway is initiated by 
Dicer processing dsRNA into ~22 nucleotide small interfering RNAs (siRNA). b) The 
siRNAs are integrated into a multicomponent nuclease called RISC, activating it. c) 
RISC then uses the siRNA as a guide to the target mRNA for degradation 154.   
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1.5.3. Regulation of RNA interference 
 
RNA interference controls downstream gene expression but is itself also regulated. 
dsRNA acts as the substrate from which siRNA is produced by the catalytic action of 
Dicer 162, however, the dsRNA also competes with an RNA editing process, catalysed 
by dsRNA-specific adenosine deaminases 163, which catalyse the conversion of 
adenosine to inosine 162. This RNA editing reaction causes both the elimination of 
complementarities between the dsRNA and the target RNA, and the destabilisation of 
edited RNA, making them poor substrates for Dicer 164.   
 
1.5.4. Applications of RNA interference 
 
RNAi is of much interest as a research tool in determining gene function, and 
therefore can also be implemented as a therapeutic agent. Much research has been 
focussed on RNA interference as a therapeutic approach for the treatment of various 
diseases 165. It is possible that many if not all human diseases, including cancer, 
autoimmune diseases, dominant genetic disorders and viral infections, caused by the 
activity of one or more genes can be corrected by RNAi based therapeutics 162 and 
RNA interference is therefore a very attractive and motivating field of research. While 
the introduction of synthetic siRNA into a system is reasonably simple and usually 
results in effective gene silencing, the results are ephemeral, however, DNA-based 
methods have the potential of being permanently established 162. Furthermore, it must 
be stressed that modes of targeting the siRNA solely to the intended diseased/affected 
cells is essential for effective therapeutic functionality.   
 
The treatment of age-related macular degeneration (AMD) was the first clinical 
application of RNAi 166; 167. RNAi based therapies are also currently being developed 
for the treatment of viral infections such as human immunodeficiency virus (HIV) 
hepatitis B and C viruses (HBV and HCV) and respiratory syncytial virus (RSV) 168. 
RNAi approaches for the treatment of neurodegenerative diseases and cancers have 
been performed 165.   
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1.6. Rationale, research question, aims and objectives 
 
1.6.1. Rationale  
 
LRP/LR has been shown to play a significant role in cancer metastasis 96, 
angiogenesis 134; 135 and cellular proliferation 75, all major hallmarks of cancer 13. 
Additionally, the downregulation of LRP/LR expression has been found to reduce the 
viability of cells 75, a desirable phenomenon with respect to cancer. The role of this 
receptor in cancer progression cannot be denied, and therefore the mechanism 
resulting in the reduction of cellular viability in cancerous cells due to decreased 
expression of LRP/LR was a topic of great interest.  
 
1.6.2. Research question 
 
Will the shRNA/siRNA-mediated downregulation of LRP/LR reduce the viability of 
A549 (human lung carcinoma) and HeLa (human cervix carcinoma) cells, and if so, 
what are the possible mechanisms for this decrease.  
 
1.6.3. Aim 
 
The aim of this study was to determine the effects of the shRNA/siRNA-mediated 
downregulation of LRP/LR on the viability of A549 (human lung carcinoma) and 
HeLa (human cervix carcinoma) cells, and to define possible mechanisms for the 
observed changes. 
 
1.6.4. Objectives 
 
• Determination of cell surface levels of LRP/LR and total levels of LRP on the 
aforementioned cell lines using flow cytometry and western blotting, respectively. 
• Successful downregulation of LRP expression in A549 and HeLa cells by 
transfection of cells with shRNA/siRNA (quantification by densitometric analysis 
of western blot signals).   
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• Determination of the effect of the shRNA/siRNA-mediated downregulation of 
LRP on cellular viability using MTT assays. 
• Identification of the possible induction of apoptosis as a result of the 
shRNA/siRNA-mediated downregulation of LRP in A549 and HeLa cells. 
o Immunofluorescence microscopy – visualisation of nuclear morphological 
changes associated with the cell undergoing programmed cell death. 
o Caspase-3 activation assay – to determine if the activity of the apoptosis-
associated protein, caspase-3, becomes upregulated in response to 
decreased LRP expression.  
• Identification of the possible decrease in cellular proliferation as a result of the 
shRNA/siRNA-mediated downregulation of LRP using a BrdU assay.  
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2. CHAPTER 2 – MATERIALS AND METHODS 
 
2.1. Cell lines and cell culture maintenance  
 
2.1.1. Cell lines 
 
The following cell lines were utilised within this study: 
• Human lung carcinoma cells (A549) – An adherent human alveolar basal 
epithelial cell line, derived from the explanted tumour of a 58-year old Caucasian 
male. 
• Human cervix carcinoma cells (HeLa) – An adherent human epithelial cell line 
from cervical carcinoma, derived from Mrs Henrietta Lacks in 1951. 
 
2.1.2. Cell culture maintenance 
 
The above mentioned cell lines were obtained from the American Type Culture 
Collection (ATCC) and were maintained and grown in cell culture plates (Corning) at 
37 °C with 95% air and 5% CO2 in DMEM (Celtic Molecular Diagnostics) media 
supplemented with 10% (v/v) heat inactivated FCS (BIOCOM biotech) and 1% (v/v) 
antibiotic penicillin and streptomycin (Gibco®). 
 
2.2. Plasmids and plasmid amplification 
 
2.2.1. Plasmids 
 
The following plasmids were utilised within this study: 
pCI-neo-GFP (appendix 1.1 – Figure A1) 
pti-H1 (appendix 1.2 – Figure A2)  
pTZ57R/T shRNA-1, 4 and 7 (appendix 1.3 – Figure A3) 
pTZ57R/T shRNA-1.1 (appendix 1.3 – Figure A3) 
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2.2.2. Plasmid amplification  
 
Plasmid amplification allows for the rapid production of large amounts of plasmid 
DNA to be utilised for experimentation. The abovementioned plasmids (section 2.2.1) 
were amplified in the following way. 
 
2.2.2.1. Production of chemically competent E. coli XL1-Blue 
 
The production of chemically competent E. coli XL1-Blue ensures that these bacteria 
are susceptible to the uptake up plasmid DNA. Chemically competent E. coli XL1-
Blue were produced as follows: 
 
A single E. coli XL1-Blue colony was picked from a freshly streaked LB plate 
(appendix 1.4.4), inoculated into 2 mL of LB liquid medium (appendix 1.5) and 
incubated at 37 °C overnight with shaking. 1 mL of this culture was then inoculated 
into 100 mL of liquid LB medium and incubated at 37 °C with shaking until the 
OD600 had reached approximately 0.25 - 0.3. The culture was chilled on ice for 15 
min and subsequently centrifuged (4 000 x rpm, 4 °C, 10 min). The supernatant was 
then discarded and the pellet resuspended in 30 mL ice cold 0.1 M CaCl2 (appendix 
1.6). This solution was incubated on ice for 30 min, centrifuged as above, the 
supernatant discarded and the pellet resuspended in 6 mL of ice cold 0.1 M CaCl2 
containing 15% glycerol (appendix 1.7). 200 µL aliquots of this solution were then 
stored at -80 °C.     
 
2.2.2.2. Transformation of plasmids into E. coli XL1-Blue 
 
Transformation refers to a procedure resulting in uptake of plasmid DNA by 
chemically competent bacteria. The transformation of plasmid DNA into E. coli XL1-
Blue was completed as follows: 
 
100 ng of plasmid DNA (either pCI-neo-GFP, pti-H1 or pTZ57R/T shRNA-1.1) was 
added to 50 µL of chemically competent E. coli XL1-Blue that had been thawed on 
ice. This solution was incubated on ice for 30 min, heat shocked at 42 °C for 45 s and 
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subsequently incubated on ice for 2 min. The transformed bacteria were then spread 
on LB plates containing 100 µg/mL ampicillin (appendix 1.4.1) and incubated at 37 
°C overnight. The plates were stored at 4 °C.    
 
2.2.2.3. Plasmid isolation 
 
Plasmid isolation is a procedure utilised to extract plasmid DNA from bacteria. The 
Plasmid DNA Purification technique was employed for the isolation of pCI-neo-GFP 
and pti-H1 plasmid DNA as well was the isolation of pTZ57R/T shRNA-1, 4 and 7 
plasmids to be utilised for DNA sequencing. The Endotoxin-free plasmid DNA 
purification technique was used for the isolation of pTZ57R/T shRNA-1.1 plasmid 
DNA to be utilised for transfections.  
 
2.2.2.3.1. Plasmid DNA Purification (mini-prep) 
 
The pCI-neo-GFP, pti-H1 and pTZ57R/T shRNA-1, 4 and 7 plasmid DNA was 
isolated using the Plasmid DNA Purification kit (Macherey-Nagel) according to the 
following protocol: 
 
A single E. coli XL1-Blue colony containing the plasmid of interest (either pCI-neo-
GFP and pti-H1 or pTZ57R/T shRNA-1, 4 and 7) was picked from a freshly streaked 
LB plate (containing 100 µg/mL ampicillin) or LB plate (containing 50 µg/mL 
ampicillin, Xgal and IPTG), respectively, inoculated in 5 mL liquid LB medium 
containing 100 µg/mL ampicillin and incubated at 37 °C overnight with shaking. The 
solution was then centrifuged (11 000 x g, 30 s, RT), the supernatant discarded and 
the pellet resuspended completely in 250 µL of buffer A1. 250 µL of buffer A2 was 
added, the solution gently mixed by inversion and incubated at RT for no longer than 
5 min until the lysate appeared clear. 300 µL of buffer A3 was added and the solution 
gently mixed by inversion, following which, it was centrifuged (11 000 x g, 5 min, 
RT). The supernatant was then decanted into the NucleoSpin® Plasmid/Plasmid 
(NoLid) Column in a collection tube, this was centrifuged (11 000 x g, 1 min, RT) 
and the flow through discarded.  600 µL of buffer A4 was then added to the 
NucleoSpin ® Plasmid/Plasmid (NoLid) Column, centrifuged (11 000 x g, 1 min, RT) 
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and the flow through discarded. The NucleoSpin ® Plasmid/Plasmid (NoLid) Column 
was then recentrifuged (11 000 x g, 2 min, RT) to dry the silica membrane and the 
collection tube was discarded. 50 µL of buffer AE was added to the NucleoSpin ® 
Plasmid/Plasmid (NoLid) Column, which had been placed in a clean collection tube, 
incubated at RT for 1 min and subsequently centrifuged (11 000 x g, 1 min, RT). The 
NucleoSpin ® Plasmid/Plasmid (NoLid) Column was discarded and the isolated 
plasmid DNA stored at -20 °C.  
 
2.2.2.3.2. Endotoxin-free plasmid DNA purification (maxi-prep) 
 
The pTZ57R/T shRNA-1.1 plasmid DNA was isolated using the Endotoxin-free 
plasmid DNA purification kit supplied by Macherey-Nagel according to the following 
protocol: 
 
A single E. coli XL1-Blue colony containing the pTZ57R/T shRNA-1.1 plasmid was 
picked from a freshly streaked LB-Amp plate, inoculated in 5 mL liquid LB medium 
containing 100 µg/mL ampicillin and incubated for approximately 8 h at 37 °C with 
shaking. This culture was diluted (1:1 000) in 300 mL liquid LB medium and 
incubated at 37 °C with shaking for 12-16 h, until the OD600 = 8. This solution was 
centrifuged (6 000 x g, 10 min, 4 °C), the supernatant discarded completely and the 
pellet resuspended in 12 mL of Buffer RES-EF. 12 mL of Buffer LYS-EF was added, 
mixed gently by inversion and the solution incubated for 5 min at RT. 12 mL of 
Neutralization Buffer NEU-EF was added to the suspension, the solution inverted 10-
15 times and the lysate incubated on ice for 5 min. 35 mL of Equilibration Buffer 
EQU-EF was applied to a column filter inserted into a NucleoBond® Xtra Column 
and was allowed to empty by gravity flow.  The cell lysate solution was inverted 
several times to ensure homogeneity, loaded into the column and allowed to clear by 
gravity flow. 10 mL of Buffer FIL-EF was then added, the column allowed to empty 
by gravity flow and the flow through discarded. 90 mL of Buffer ENDO-EF was 
added to the NucleoBond® Xtra Column and was allowed to empty by gravity flow, 
following which 45 mL of Buffer WASH-EF was added and also allowed to empty by 
gravity flow (the flow through was discarded between each step). 15 mL of 
prewarmed (to 50 °C) Elution Buffer ELU-EF was then added to the NucleoBond® 
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Xtra Column and the flow through collected in a clean 50 mL Falcon tube. 0.7 
volumes of RT isopropanol was added to the eluent, the solution vortexed and 
allowed to incubate at RT for 2 min. The plunger from a 30 mL syringe was removed 
and a NucleoBond® Finalizer attached to the outlet. The eluent-isopropanol solution 
was then added to the syringe, the plunger inserted, the solution gently pushed 
through the NucleoBond® Finalizer and the flow through discarded. The 
NucleoBond® Finalizer was removed from the syringe, the plunger removed and the 
NucleoBond® Finalizer was reattached to the syringe. 5 mL of endotoxin-free 70% 
ethanol was filled into the syringe, the plunger inserted, the solution pressed gently 
through the NucleoBond® Finalizer and the flow through discarded. The 
NucleoBond® Finalizer filter membrane was then dried by strongly passing air 
through the syringe and collecting and residual moisture on a tissue (the 
NucleoBond® Finalizer was removed from the syringe, the plunger removed and the 
NucleoBond® Finalizer was reattached to the syringe each time air was pressed 
through). Finally, 500 µL of Buffer TE-EF was added to a 1 mL syringe attached to 
the NucleoBond® Finalizer, the plasmid DNA eluted drop by drop by slowly 
inserting the plunger, and stored at -20 °C.  
 
2.3. Determination of cell surface LRP/LR levels 
 
The amount of LRP/LR on the surface of A549 and HeLa cells was a determined 
using flow cytometry according to the following protocol: 
 
A549 and HeLa cells were detached using trypsin/EDTA (Separations), centrifuged 
(4 000 x rpm, 5 min, RT) and fixed for 10 min in 4% paraformaldehyde (appendix 
3.1) at 4 °C. After fixing, cells were pelleted by centrifugation (4 000 x rpm, 10 min, 
4 °C), the supernatant discarded and the pellet resuspended in 1 mL Epics™ Sheath 
Fluid (Beckman Coulter). 500 µL of the cell suspension was then transferred into a 
second eppendorf tube (to be used as a control), the two cell suspensions centrifuged 
(4 000 x rpm, 10 min, 4 °C) and the supernatant discarded. The control pellet was 
resuspended in 100 µL Epics™ Sheath Fluid and the experimental pellet in 100 µL of 
a 30 µg/ml solution of the anti-LRP specific primary antibody IgG1-iS18 in Epics™ 
Sheath Fluid; these were incubated at RT for 1 h. The cells were subsequently washed 
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in 200 µL Epics™ Sheath Fluid, centrifuged (5 000 x rpm, 1 min, RT) and the 
supernatant discarded (this step was repeated thrice). The control and experimental 
pellets were resuspended in 100 µL of a 30 µg/ml solution of the Goat Anti-Human 
IgG-FITC secondary antibody (Beckman Coulter) in Epics™ Sheath Fluid and 
incubated for 1 h at RT in the dark. Following incubation, cells were washed with 200 
µL Epics™ Sheath Fluid, centrifuged (5 000 x rpm, 1 min, RT) and the supernatant 
discarded (this step was repeated thrice). The pellets were then resuspended in 500 µL 
Epics™ Sheath Fluid and 10 000 cells from each solution were analysed using a 
fluorescence activated cell scanner (Beckman Coulter). 
 
2.4. Determination of total LRP levels  
 
2.4.1. Cell lysis 
 
Cell lysis is a process in which the cell membrane is disrupted chemically, 
mechanically or physically, resulting in the release of cellular contents such as 
proteins, DNA and RNA. A549 and HeLa cells were lysed according to the following 
protocol: 
 
The medium from confluent A549 and HeLa cells was discarded, the cells washed 
with DPBS (Gibco®) and 500 µL of lysis buffer (appendix 2.1) added. The cells were 
detached using cell scrapers (BD Biosciences), the cell suspension transferred to 
eppendorf tubes and incubated on ice for 15 min. Following incubation, the cell 
lysates were centrifuged (14 000 x rpm, 2 min, RT) and the supernatant stored at -20 
°C.  
 
2.4.2. BCA assay 
 
The Bicinchoninic acid (BCA) assay is a biochemical assay utilised to determine the 
amount of protein in a particular sample. This assay is based on the reduction of Cu2+ 
to Cu+ by proteins, resulting in the formation of a purple coloured product, which can 
be measured spectrophotometrically at 562 nm. Known amounts of bovine serum 
albumin (BSA) are used as standards to create a calibration curve from which the 
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amount of protein contained in the samples can be determined. The BCA assay 
(Sigma-Aldrich) was completed according to the following protocol: 
 
 Various amounts (0, 0.2, 0.4, 0.6, 0.8 and 1 mg/mL) of BSA were prepared and 25 
µL of each standard in addition to the prepared cell lysates (diluted 1:5 in dH20) were 
loaded in triplicate in the wells of a 96 well plate. The two BCA reagents (copper (II) 
sulfate and bicinchoninic acid) were mixed in a 1:50 ratio and 200 µL of this solution 
added to each well (containing the standards and cell lysates). The plate was then 
incubated at 37 °C for 30 min and the absorbance of each well measured using a 
microtiter plate reader at 562 nm. The amount of protein contained in the cell lysates 
was determined using the constructed calibration curve. 
 
2.4.3. Preparation of protein samples for SDS-PAGE 
 
Protein samples were diluted with dH20 to 1mg/mL mixed in a 1:5 ratio with 5 X 
sample loading dye (appendix 2.2) and stored at 4 °C.  
 
2.4.4. SDS-PAGE 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
technique used to separate proteins according to their molecular weight. SDS is an 
anionic detergent that results in the denaturation of secondary and tertiary protein 
structures. Additionally, SDS binds to unfolded proteins and confers a net negative 
charge along the length of the polypeptide. The proteins from the cell lysates were 
subjected to SDS-PAGE according to the following protocol: 
 
Aliquots each containing 5 µg of total cellular proteins in sample loading dye were 
heated at 95 °C for 5 min before being stacked and resolved (230 V, 230 mA) on a 
5% stacking (appendix 2.3.7.2) and 12% separating (appendix 2.3.7.1) sodium 
dodecyl sulphate-polyacrylamide gel, respectively.   
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2.4.5. Transfer of proteins from the gel to PVDF membrane (western 
blotting) 
 
The resolved sodium dodecyl sulphate-polyacrylamide gel was placed above a 0.45 
µm PVDF membrane (Separations), which had been activated in ethanol, 
subsequently soaked in transfer buffer (appendix 2.3.8) and sandwiched between 6 
filter papers wetted in transfer buffer.  The proteins resolved on gels were electro-
transferred (350 mA) for 45 min onto the PVDF membrane. 
 
2.4.6. Immunodetection of LRP and β-actin expression levels   
 
Immunodetection is a technique making use of antibodies to detect the presence of a 
specific antigen, and can be used for the analysis of protein expression. 
Immunodetection of LRP and β-actin expression levels was completed according to 
the following protocol: 
 
Following transfer, the PVDF membrane was blocked with 3% BSA in PBS-Tween 
(appendix 2.6) for 1 h at RT with gentle shaking and subsequently incubated in a 1:10 
000 dilution of either the LRP specific primary antibody IgG1-iS18 (Affimed 
Therapeutics) or the β-actin detection antibody Anti-β-Actin−Peroxidase (Sigma-
Aldrich) in 3% BSA in PBS-Tween for 1h.  
 
In the case of LRP detection, the membrane was then washed three times for 10 min 
each in PBS-Tween (appendix 2.5) with shaking and subsequently incubated in a 1:10 
000 dilution of a peroxidase-conjugated secondary antibody anti-human IgG-POD 
(Santa Cruz Biotechnology) in 3% BSA in PBS-Tween for 1 h in the dark with 
shaking.  
 
The membranes (both for LRP and β-actin detection) were then finally washed three 
times for 10 min each in PBS-Tween with shaking.  
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The expression of the protein of interest was detected using supersignal the west pico 
chemiluminescent substrates (Separations) mixed in a 1:1 ratio. The protein bands 
were visualised by exposure to X-ray film (Separations), which was subsequently 
developed and fixed using developer (Sigma-Aldrich) and fixer (Sigma-Aldrich) 
solutions, respectively.   
 
2.4.7. Densitometric analysis 
 
To quantitatively determine the relative LRP expression levels, densitometric analysis 
was completed. Subsequent to immunodetection, an image of the X-ray film was 
obtained using the GS-800 Calibrated Densitometer and densitometric analysis 
completed using the Quantity One – 4.5.2 software. The band intensities were 
calculated and background noise subtracted, producing a calibration curve. The area 
under the curve indicates IOD (Integrated Optical Density) and this parameter was 
used to compare the levels of LRP expression in A549 and HeLa cells.  
 
2.5. Determination of A549 and HeLa transfectability  
 
A549 and HeLa cells were transfected with a pCI-neo-GFP plasmid encoding the 
green fluorescent protein (GFP) using TransIT®-LT1 Transfection Reagent 
(Invitrogen); the visualisation of green fluorescence using an immunofluorescence 
microscope would indicate that the aforementioned cells were transfectable.  
 
2.5.1. Transfection of A549 and HeLa cells with pCI-neo-GFP 
 
Transfection refers to the process by which foreign nucleic acids are introduced into 
mammalian cells. A549 and HeLa cells were transfected with pCI-neo-GFP according 
to the following protocol: 
 
4 x 105 A549 and 3.5 x 105 HeLa cells were plated in 6 cm plates (Corning) 
containing sterile microscope coverslips. 24 h later, 7.5 µL of prewarmed (to RT) and 
vortexed TransIT®-LT1 reagent was diluted in 250 µL DMEM in a sterile eppendorf 
tube, and this gently mixed. 2.5 µg of the pCI-neo-GFP plasmid was then added to the 
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diluted TransIT®-LT1 reagent, gently mixed and this solution allowed to incubate at 
RT for 15 min. Following this incubation, the TransIT®-LT1 reagent – DNA 
complex was added drop wise to the previously plated A549 and HeLa cells, which 
were then further incubated for 24 h in a humidified incubator at 37 °C with 95% air 
and 5% CO2. 
 
2.5.2. Immunofluorescence microscopy 
 
The microscope coverslips were removed from the cell culture plates, fixed in 2% 
paraformaldehyde (appendix 4.1) for 15 min, rinsed in several changes of PBS and 
blocked in 0.25% Triton X-100 containing 0.5% BSA in PBS (appendix 4.2) for 10 
min. The coverslips were then incubated for 5 min in a 1:100 dilution of a 2 mg/mL 
stock solution of the nuclear stain Hoechst 33342 (Sigma-Aldrich) and subsequently 
rinsed in several PBS changes. 50 µL of Gel Mount™ (Sigma-Aldrich) was placed on 
a clean microscope slide, the coverslips mounted cell side down and allowed to dry 
for approximately 3 h. These slides were stored in the dark at 4 °C until viewed on an 
immunofluorescence microscope at 100 X magnification.  
 
2.6. Production of shRNA  
 
shRNA directed against human LRP mRNA target sequences were produced to 
potentially downregulate the expression of this protein in A549 and HeLa cells. Prof. 
Marco Weinberg kindly designed the shRNAs, and these were produced together with 
fellow M. Sc. student Miss Danielle Gonsalves.   
 
2.6.1. Design of oligonucleotides 
 
shRNAs-1, 4 and 7 were designed (shRNA-4 and -7 homologous to sequences 
previously used in murine studies 169, and the shRNA-1 sequence was identified using 
The RNAi Consortium - http://www.broadinstitute.org/rnai/trc) to be expressed from 
the H1 RNA Pol III promoter. Each shRNA “guide strand” sequence was designed to 
be 21 nucleotides in length. The shRNA expression constructs were designed with the 
guide strand on the 3’ arm, a poly T termination signal, and includes a full H1 
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promoter sequence to constitute a complete expression cassette (appendix 5.1). To 
prepare the shRNA cassettes, the H1 RNA Pol III promoter was used as a template in 
a nested PCR, whereby the sequences corresponding to the shRNAs were 
incorporated into two reverse primers (one for the primary PCR and one for the 
secondary PCR). The same forward primer, which is complementary to the start of the 
H1 promoter, was used in both the primary and secondary PCRs. The PCR products 
therefore contained the full H1 promoter sequence that precedes the sequences coding 
for the shRNAs. The PCR products coding for the shRNA expression constructs 
contained a single terminal 3´ A-overhang resulting from Taq polymerase activity and 
a final extension step and were therefore suitable for TA cloning.  
 
2.6.2. Nested PCR amplification of oligonucleotides 
 
The oligonucleotides were amplified in two rounds (nested PCR reaction) according 
to the following protocol.      
 
2.6.2.1. Primary PCR 
 
• Template DNA – pTZ57R/T shRNA-1, 4 and 7  
pti-H1 plasmid 
 
• Forward Primer – pTZ57R/T shRNA-1, 4 and 7   
5’ GATCTCTAGAGCGAACGCTGACGTCATCAA 
 
• Reverse Primer – pTZ57R/T shRNA-1 
5’ CCATTTGGGTCAGGAATGGCAACAATTGCACGAGCGGGTCCGAGTG 
GTCTCATAC 
 
• Reverse Primer – pTZ57R/T shRNA-4 
5’ CTTCCTGGGTCAGGAGAAGGCTGCCTGGATCTGGCGGGTCCGAGTG 
GTCTCATAC 
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• Reverse Primer – pTZ57R/T shRNA-7 
5’ GAATTTGGGTCAGGAATTCCTCCTTGGTCACTGCCGGGTCCGAGTG 
GTCTCATAC 
 
50 pg pti-H1 plasmid, 0.05 µmol forward primer, 0.05 µmol respective reverse 
primer, 200 µM of each dNTP (A, T, G and C) (Fermentas), 2.5 mM MgCl2 
(Fermentas), 1.25 units of Taq polymerase (Fermentas), 10 µL of 1 X Taq polymerase 
buffer (Fermentas) and nuclease free water (Fermentas) to make the reaction up to 50 
µL was combined on ice in a sterile nuclease-free 200 µL PCR tube, and subsequently 
placed in a thermocycler. The solutions were initially denatured for 3 min at 95 °C, 30 
cycles of denaturation for 30 s at 95 °C, annealing for 30 s at 60 °C and extension for 
30 s at 72 °C was completed before a final extension step for 15 min at 75 °C. The 
reaction 1 PCR product was visualised by electrophoresis on a 1% agarose gel 
(appendix 5.5) and stored at -20 °C. 
 
2.6.2.2. Secondary PCR 
 
• Template DNA – pTZ57R/T shRNA-1, 4 and 7 
Respective PCR product from reaction 1 
 
• Forward Primer – pTZ57R/T shRNA-1, 4 and 7   
5’ GATCTCTAGAGCGAACGCTGACGTCATCAA 
 
• Reverse Primer – pTZ57R/T shRNA-1 
5’ AAAAAAGCTCGTGCAATTGTTGCCATTTGGGTCAGGAATG 
 
• Reverse Primer – pTZ57R/T shRNA-4 
5’ AAAAAAGCCAGATCCAGGCAGCCTTCCTGGGTCAGGAGAA 
 
• Reverse Primer – pTZ57R/T shRNA-7 
5’ AAAAAAGGCAGTGACCAAGGAGGAATTTGGGTCAGGAATT 
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Reaction 2 constituents and cycling parameters as described above (section 2.6.2.1).  
The reaction 2 PCR product was visualised by electrophoresis on a 1% agarose gel 
and stored at -20 °C.  
 
2.6.3. PCR clean-up 
 
A single band of DNA needed to be isolated from the gel since multiple bands were 
visualised when the PCR products were electrophoretically resolved. For this, the 
Wizard® SV Gel and PCR Clean-Up System (Promega) was utilised according to the 
following protocol: 
 
Following electrophoresis, the band of interest was excised from the gel, placed in a 
1.5 mL microcentrifuge tube, and dissolved in 10 µL Membrane Binding Solution per 
10 mg gel by vortexing and incubation at 65 °C. The dissolved gel was then 
transferred into a SV Minicolumn inserted in a Collection Tube, incubated at RT for 1 
min, centrifuged (16 000 x g, 1 min, RT) and the flow through discarded. 700 µL of 
Membrane Wash Solution was then added, centrifuged as before and the flow through 
discarded. 500 µL of Membrane Wash Solution was added, centrifuged as before and 
the flow through discarded. The assembly was then recentrifuged (as before) with the 
microcentrifuge lid open to allow for the evaporation of residual ethanol. 50 µL of 
Nuclease-Free Water was added to the SV Minicolumn, which had been transferred to 
a clean 1.5 mL microcentrifuge tube, incubated at RT for 1 min, centrifuged as above 
and the SV Minicolumn discarded. The cleaned-up PCR products were visualised by 
electrophoresis on a 1% agarose gel (appendix 5.2 – Figure A5) and stored at -20 °C.   
 
2.6.4. Ligation reaction 
 
A ligation reaction refers to the insertion of a DNA sequence of interest into a vector 
(plasmid), yielding circular double stranded DNA. The cleaned up PCR product was 
ligated into a TA cloning vector using the InsTAclone™ PCR Cloning Kit 
(Fermentas) according to the following protocol: 
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0.17 pmol of the pTZ57R/T vector, 6 µL of 5 X Ligation Buffer, 0.52 pmol of PCR 
product, 5 Weiss units of T4 DNA Ligase and nuclease-free water to make the 
reaction volume up to 30 µL was combined in a nuclease-free 200 µL microcentrifuge 
tube on ice and vortexed briefly. This ligation mixture was incubated at RT for 1 h 
and stored at -20 °C.  
 
2.6.5. Transformation reaction 
 
The transformation of the plasmids (pTZ57R/T shRNA-1, 4 and 7) obtained from the 
ligation reaction (section 2.6.4) into E. coli XL1-Blue was completed using the 
InsTAclone™ PCR Cloning Kit (Fermentas) according to the following protocol:  
 
The day before transformation, a single colony of E. coli XL1-Blue from a freshly 
streaked LB plate was inoculated into 2 mL of C-medium and incubated at 37 °C 
overnight with shaking. 1.5 mL of pre-warmed (to 37 °C) C-medium was added to 
150 µL of the overnight bacterial culture and this was incubated at 37 °C for 20 min 
with shaking. The bacterial cells were pelleted by centrifugation (16 000 x g, 1 min, 
RT) and the supernatant discarded. The pellet was resuspended in 300 µL of T-
solution (T-solutions A and B mixed in a 1:1 ratio), incubated on ice for 5 min, 
centrifuged as before and the supernatant discarded. The pellet was resuspended in 
120 µL of T-solution and incubated on ice for 5 min.  50 µL of this solution was then 
transferred to clean microcentrifuge tubes containing 2.5 µL of the respective ligation 
mixture, which had been chilled on ice for 2 min, the solution mixed and 
subsequently incubated on ice for 5 min. The cells containing the DNA were then 
immediately plated onto pre-warmed (to 37 °C) LB plates containing 50 µg/mL 
ampicillin, Xgal and IPTG to allow for blue/white selection (appendix 5.3 – Figure 
A6) 
 
2.6.6. Plasmid isolation 
 
Isolation of pTZ57R/T shRNA-1, 4 and 7 plasmids from 10 white colonies each from 
E. coli XL1-Blue which had been plated on LB plates containing 50 µg/mL 
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ampicillin, Xgal and IPTG was completed according to the protocol described in 
section 2.2.2.3.1.   
 
2.6.7. Plasmid DNA sequencing 
 
The 10 samples each of isolated pTZ57R/T shRNA-1, 4 and 7 plasmid DNA was 
sequenced by Inqaba Biotec and the resulting chromatograms viewed using Chromas 
Lite 2.01. The plasmid DNA insert sequences were then compared to their 
complementary target sequences. One isolation of the pTZ57R/T shRNA-1 plasmid 
(labelled as pTZ57R/T shRNA-1.1) was identical to its target sequence and was 
therefore utilised in the following experiments. 
 
2.6.8. Retransformation of pTZ57R/T shRNA-1.1 
 
The pTZ57R/T shRNA-1.1 plasmid was then retransformed into E. coli XL1-Blue 
according to the protocol outlined in section 2.2.2.2.  
  
2.6.9. Isolation of pTZ57R/T shRNA-1.1 
 
pTZ57R/T shRNA-1.1 plasmid DNA was isolated from a single colony of E. coli 
XL1-Blue according to the protocol outlined in section 2.2.2.3.2.  
 
2.7. Transfection of cells with pTZ57R/T shRNA-1.1 and determination of LRP 
downregulation 
 
2.7.1. Transfection 
 
A549 and HeLa cells were transfected with pTZ57R/T shRNA-1.1 according to the 
following protocol: 
 
24 h before transfection, 4 x 105 A549 and 3.5 x 105 HeLa cells were plated in the 
wells of a 6 well plate. 7.5 µL of prewarmed (to RT) and vortexed TransIT®-LT1 
reagent was added to 250 µL of DMEM in a sterile eppendorf tube, and this solution 
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gently mixed. 2.5 µg of the pTZ57R/T shRNA-1.1 plasmid was then added to the 
diluted TransIT®-LT1 reagent, gently mixed and allowed to incubate at RT for 15 
min. Following this incubation, the TransIT®-LT1 reagent-DNA complex was added 
drop wise to the previously plated A549 and HeLa cells, which were then allowed to 
incubate for 72 h in a humidified incubator at 37 °C with 95% air and 5% CO2. 
 
2.7.2. Determination of LRP downregulation 
 
72 h post-transfection, A549 and HeLa cells were lysed, their protein content 
quantified, electrophoresis samples prepared, proteins stacked and resolved on a 5% 
stacking and 12% separating sodium dodecyl sulfate polyacrylamide gel, respectively, 
resolved proteins transferred from the gel to a 0.45 µm PVDF membrane, pTZ57R/T 
shRNA-1.1 transfected and non-transfected LRP expression levels determined by 
immunodetection and pTZ57R/T shRNA-1.1 transfected LRP expression levels 
compared to non-transfected controls using densitometry as described above in 
sections 2.4.1, 2.4.2, 2.4.3, 2.4.4, 2.4.5, 2.4.6, and 2.4.7, respectively.   
 
2.8. Purchase of siRNA directed against LRP mRNA, transfections and 
determination of LRP expression levels  
 
Since transfecting A549 and HeLa cells with the pTZ57R/T shRNA-1.1 plasmid did 
not result in a significant downregulation of LRP expression in A549 and HeLa cells, 
siRNA targeting the open reading frame of the human LRP gene (ON-
TARGETplus® siRNA – Human LAMR1) was purchased from Thermo Scientific 
Dharmacon® and utilised in all subsequent experiments. Additionally, non-targeting 
siRNA (ON-TARGETplus® control siRNA – Non-Targeting siRNA 1) to be used as 
a positive control as well as the recommended transfection reagent (DharmaFECT® 1 
transfection reagent) was purchased from this company.  
 
Although both shRNA and siRNA can be used to bring about similar outcomes 
(reduction in mRNA and protein expression), they are intrinsically different 
molecules 170. siRNA are chemically synthesised 21 nt molecules, while shRNA are 
vector based and make use of the cellular machinery for their expression.     
! 50!
2.8.1. Transfection of A549 and HeLa cells with siRNA-LAMR1 
 
4 X 105 A549 and 3.5 X 105 HeLa cells were seeded in the wells of a 6 well plate. 24 
h later, 150 µmol (for A549 cells) or 200 µmol (for HeLa cells) of siRNA-LAMR1 
and 6 µL of DharmaFECT® 1 transfection reagent were each concurrently diluted in 
DMEM, each to a final volume of 200 µL, the contents of each tube was gently mixed 
and allowed to incubate for 5 min at RT. The diluted siRNA-LAMR1 solution was 
then added to the diluted DharmaFECT® 1 transfection reagent, mixed gently and 
incubated for 20 min at RT. The culture medium was removed from the plated A549 
and HeLa cells and 1600 µL of DMEM containing 10% (v/v) FCS added to the 
siRNA-reagent solution, which the cells were then grown in for 72 h in a humidified 
incubator at 37 °C with 95% air and 5% CO2.   
 
2.8.2. Determination of LRP expression levels 
 
72 h post-transfection, A549 and HeLa cells were lysed, their protein content 
quantified, electrophoresis samples prepared, proteins resolved on a 12% sodium 
dodecyl sulfate polyacrylamide gel, resolved proteins transferred from the gel to a 
0.45 µm PVDF membrane, siRNA-LAMR1 transfected and non-transfected LRP 
expression levels determined by immunodetection and siRNA-LAMR1 transfected 
LRP expression levels compared to non-transfected controls using densitometry as 
described above in sections 2.4.1, 2.4.2, 2.4.3, 2.4.4, 2.4.5, 2.4.6, and 2.4.7, 
respectively.   
 
2.9. Examination of cellular viability 
 
An MTT assay was utilised to assess cellular viability. MTT is converted to formazan 
crystals by the enzyme mitochondrial succinate dehydrogenase, present only in viable 
cells. The absorbance of the formazan crystals is therefore directly proportional to 
cellular viability.  
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2.9.1. Transfection of A549 and HeLa cells with siRNA-scr and siRNA-
LAMR1 
 
A549 and HeLa cells were seeded in the wells of a 96 well plate and transfected with 
siRNA-LAMR1 (appendix 6.1). Additionally cells were transfected with 50 µmol of 
the ON-TARGETplus® control siRNA – Non-Targeting siRNA 1 (here designated 
siRNA-scr) and incubated in 8 mM PCA (Sigma-Aldrich) (appendix 6.2) for negative 
and positive control purposes, respectively. 72 h post-transfect/incubation, 10 µg of 
MTT (Separations) (appendix 6.3) was added to each well and the cells allowed to 
incubate (as before) for 2 h. The culture medium was subsequently removed, the 
formazan crystals in each well dissolved in 200 µL DMSO (Monitoring and Control 
Laboratories) and the absorbance of this solution measured using a microtiter plate 
reader at 570 nm.  
 
2.9.2. Incubation of A549 and HeLa cells with siRNA-scr and 
DharmaFECT® 1 transfection reagent 
 
0.6 X 104 A549 and 3 X 103 HeLa cells were seeded in the wells of a 96 well plate. 24 
h later, cells were incubated with 50 µmol siRNA-scr, 0.2 µL of DharmaFECT® 1 
transfection reagent or both (all in DMEM containing 10% (v/v) FCS) to a final 
volume of 100 µL in a humidified incubator at 37 °C with 95% air and 5% CO2. 72 h 
later, 10 µg of MTT was added to each well and the cells allowed to incubate (as 
before) for 2 h. The culture medium was subsequently removed, the formazan crystals 
in each well dissolved in 200 µL DMSO and the absorbance of this solution measured 
using a microtiter plate reader at 570 nm.  
  
2.10. Examination of apoptotic nuclear morphology 
 
A549 and HeLa cells were seeded in the wells of a 6 well plate containing microscope 
coverslips and transfected with siRNA-LAMR1 as indicated above in section 2.8.1. 
Additionally cells were transfected with siRNA-scr and incubated in 8 mM PCA for 
negative and positive control purposes, respectively. 72 h post-transfection, the 
microscope coverslips were removed, the cells stained with Hoechst 33342 for 
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visualisation of nuclear morphology and subsequently prepared for 
immunofluorescence microscopy according to the protocol outlined in section 2.5.2.   
 
2.11. Examination of caspase-3 activity 
 
A549 and HeLa cells were seeded in the wells of a 6 well plate and transfected with 
siRNA-LAMR1 as indicated above in section 2.8.1. Additionally cells were 
transfected with siRNA-scr and incubated in 8 mM PCA for negative and positive 
control purposes, respectively. 72 h post-transfection, cell lysates were analysed for 
caspase-3 activity using a colorimetric Caspase-3 Assay Kit (Sigma-Aldrich) 
according to the following protocol.  
 
A549 and HeLa cells were detached using trypsin/EDTA and resuspended in DMEM 
containing 1% (v/v) penicillin/streptomycin and 10% (v/v) FCS. 107 cells from each 
sample was centrifuged (600 x g, 10 min, 4 °C), the supernatant discarded, the pellet 
washed in 1 X PBS, centrifuged as above and the supernatant discarded. Each pellet 
was then resuspended in 1 X Lysis buffer, incubated on ice for 20 min and 
centrifuged (20 000 x g, 10 min, 4 °C). 5 µL of each lysate was then added to the 
wells of a flat bottom 96 well plate containing 2 mM of the caspase-3 substrate Ac-
DEVD-pNA and 1 X Assay Buffer was added to a total volume of 100 µL. The plate 
was incubated in a humidified incubator at 37 °C with 95% air and 5% CO2 for 24 h 
and the absorbance of each well subsequently measured using a microtiter plate 
reader at 405 nm.   
 
2.12. Assessment of cellular proliferation 
 
A549 and HeLa cells were seeded in the wells of a 96 well plate and transfected with 
siRNA-LAMR1 (appendix 6.1). Additionally cells were transfected with siRNA-scr 
and incubated in 100 µg/mL Doxycycline (Sigma-Aldrich) (appendix 7.1) for 
negative and positive control purposes, respectively. 72 h post-transfection, the 
percentage of proliferative A549 and HeLa cells in each sample was determined using 
a BrdU Cell Proliferation Assay (Calbiochem®) according to the following protocol: 
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72 h post-transfection, 20 µL of the BrdU Label solution (diluted 1:2 000 in DMEM 
containing 1% (v/v) penicillin/streptomycin and 10% (v/v) FCS) was added to each 
well and the plate allowed to incubate overnight (∼14 h) in a humidified incubator at 
37 °C with 95% air and 5% CO2. The contents of the plate was then removed, 200 µL 
of Fixative/Denaturing solution added to each well and the plate incubated for 30 min 
at RT. The contents of the plate was removed, 100 µL of diluted (1:100 in Dilution 
Buffer) 100 X Anti-BrdU antibody added to each well and the plate incubated for 1 h 
at RT. The plate was washed thrice with 1 X Wash Buffer and the subsequently 
blotted dry on paper towels. 100 µL of diluted (1:1 000 in Conjugate Diluent) 
Peroxidase Goat Anti-Mouse IgG HRP Conjugate antibody was added to each well, 
incubated for 30 min at RT and subsequently washed thrice (as before). The entire 
plate was then flooded with dH2O, the contents of the wells removed and the plate 
dried by tapping gently on paper towels. 100 µL of the substrate solution was added 
to each well, and incubated in the dark at RT for 15 min. 100 µL of Stop Solution was 
then added to each well (in the same order as the Substrate Solution) and the 
absorbance of each well immediately measured using a microtiter plate reader at 540 
nm. 
 
2.13. Statistical analysis 
 
Data was statistically analysed with a Dunnett’s test using GraphPad InStat. Results 
were considered statistically significant when the p-value was less than 0.05.   
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3. CHAPTER 3 – RESULTS 
  
3.1. Determination of cell surface LRP/LR and total LRP levels on A549 and 
HeLa cells 
 
3.1.1. Determination of cell surface LRP/LR levels  
 
The amount of LRP/LR on the surface of A549 and HeLa cells was determined by 
flow cytometry; the aforementioned cells were incubated with the anti-LRP specific 
primary antibody IgG1-iS18 and subsequently with the Goat anti-human IgG-FITC 
secondary antibody (section 2.3).  
 
The resulting histograms (Figure 3.1) demonstrate that 83% of A549 cells and 80% of 
HeLa cells display LRP/LR on their surface.  
 
3.1.2. Determination of total LRP levels 
 
Since this protein has numerous cellular locations (namely the cell surface, the 
cytoplasm, the perinuclear compartment and the nucleus) the total level of LRP in 
A549 and HeLa cells was assessed using western blotting and quantitatively 
determined using densitometric analysis (section 2.4).  
 
Western blot analysis revealed a band at a molecular weight of 37 kDa, representative 
of the 37 kDa laminin receptor precursor (LRP) (Figure 3.2), confirming its 
expression in the aforementioned cell lines (β-actin was used as a loading control). 
Additionally, densitometric analysis of the western blot signals revealed a non-
significant (p > 0.05) difference between the LRP expression levels of A549 and 
HeLa cells (Figure 3.2). The 67 kDa form of the receptor was not detected in the 
western blots (data not shown).      
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Figure 3.1 – Flow cytometric analysis of surface LRP/LR levels on A549 and HeLa cells. Red and blue peaks are representative of non-
labelled and cells incubated with the anti-LRP IgG1-iS18 antibody and subsequently with the goat anti-rabbit IgG human ads-FITC secondary 
antibody, respectively. 83% and 80% of a) A549 and b) HeLa cells, respectively, displayed LRP on their surface.  
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Figure 3.2 – Determination of total cellular LRP levels in A549 and HeLa cells. Proteins were extracted, separated on a 12% SDS-PAGE 
and western blotting performed using primary antibodies directed against LRP or β-actin (used as a loading control). Densitometric analyses of 
western blot signals reveal that A549 (lanes 1-3) and HeLa (lanes 4-6) cells express similar levels of LRP (p > 0.05).   
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3.2. Determination of A549 and HeLa cell transfectability 
 
The introduction of plasmid DNA and siRNA into A549 and HeLa cells, to 
potentially decrease their expression of LRP, was imperative for the completion of 
this study; hence, the transfectability of the aforementioned cells was determined. 
A549 and HeLa cells were transiently transfected with a plasmid encoding for the 
green fluorescent protein (pCI-neo-GFP), stained with the fluorescent nuclear dye 
Hoechst 33342 and subsequently viewed using immunofluorescence microscopy 
(section 2.5).  
 
The resulting images (Figure 3.3) reveal both blue and green fluorescence; the 
presence of green fluorescence indicates produced green fluorescent protein, therefore 
signifying that the A549 and HeLa cells are transfectable. 
 
3.3. Determination of LRP downregulation in A549 and HeLa cells post-
transfection with pTZ57R/T shRNA-1.1 
 
The level of LRP expression in A549 and HeLa cells post-transfection with the 
produced pTZ57R/T shRNA-1.1 plasmid was determined using western blotting and 
densitometric analysis (section 2.7).  
 
Densitometric analysis of the obtained western blot signals (Figure 3.4) revealed that 
pTZ57R/T shRNA-1.1 transfected A549 and HeLa cells exhibited non-significant (p 
> 0.05) differences in their expression of LRP, compared to non-transfected cells 
(which had been set to 100%) (β-actin was used as a loading control).  
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Figure 3.3 – Determination of A549 and HeLa cell transfectability. 24 h post-transfection of A549 and HeLa cells with a plasmid 
encoding for the green fluorescent protein (pCI-neo-GFP), cells were stained with the fluorescent nuclear dye Hoechst 33342 and viewed on 
an immunofluorescence microscope. The resultant images show both blue and green fluorescence, indicating that these cell lines are 
transfectable.  
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Figure 3.4 – LRP expression in A549 and HeLa cells post-transfection with shRNA-1.1. The expression levels of LRP in A549 and HeLa 
cells was investigated 72 h post-transfection with shRNA-1.1. Densitometric analysis of western blot signals revealed non-significant (p > 0.05) 
differences in LRP expression in a) A549 and b) HeLa cells, respectively, compared to non-transfected cells.
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3.4. Determination of LRP downregulation in A549 and HeLa cells post-
transfection with siRNA-LAMR1 
 
The level of LRP expression in A549 and HeLa cells post-transfection with the 
purchased siRNA-LAMR1 was determined using western blotting and densitometric 
analysis (section 2.8).  
 
Densitometric analysis of the western blot signals (Figure 3.5) revealed that siRNA-
LAMR1 transfected A549 and HeLa cells displayed a significant (** p < 0.01) 83% 
and 60% reduction in LRP expression, respectively, compared to non-transfected cells 
(which had been set to 100%) (β-actin was used as a loading control).  
 
3.5. Determination of the effect of the siRNA-mediated downregulation of LRP 
expression on cellular viability 
 
The effect of the siRNA-mediated downregulation of LRP expression on cellular 
viability in the aforementioned cell lines was determined using an MTT assay. Cells 
were incubated with 8 mM PCA (a compound known to decrease cellular viability 
through the induction of apoptosis 171) as a positive control and transfected with a 
non-targeting siRNA (siRNA-scr) as a negative control (section 2.9.1). Non-
transfected, 8 mM PCA and siRNA-LAMR1 values were compared to siRNA-scr 
values, which had been set to 100%.   
 
siRNA-LAMR1 treated A549 and HeLa cells revealed a significant (* p < 0.05, ** p 
< 0.01) 13% and 18% reduction in cellular viability, respectively, compared to 
siRNA-scr treated cells (Figure 3.6).   
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Figure 3.5 - siRNA-mediated downregulation of LRP expression in A549 and HeLa cells. The expression level of LRP in A549 and HeLa 
cells was investigated 72 h post-transfection with siRNA-LAMR1. Densitometric analysis of western blot signals revealed a significant (** p < 
0.01) 83% and 60% reduction in LRP expression in a) A549 and b) HeLa cells, respectively, compared to non-transfected controls.   
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Figure 3.6 – The effect of the siRNA-mediated downregulation of LRP expression on cellular viability in A549 and HeLa cells. The 
viability of A549 and HeLa cells was analysed 72 h post-transfection using an MTT assay. siRNA-LAMR1 treated a) A549 and b) HeLa 
cells reveal a significant (* p < 0.05, ** p < 0.01) 13% and 18% reduction in cellular viability, respectively, compared to siRNA-scr treated 
cells (set to 100%) (8 mM PCA used as positive control). 
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Additionally, siRNA-scr treated cells exhibited a non-significant 14% decrease in 
cellular viability, compared to non-transfected HeLa cells (Figure 3.6b). Incubating 
HeLa cells with siRNA-scr, DharmaFECT® 1 transfection reagent or both was used 
to determine the causative agent of the observed reduction in cellular viability. An 
MTT assay was completed and the values obtained for the abovementioned samples 
were compared to control cells (containing no additions), which had been set to 100% 
(as indicated in section 2.9.2).  
 
This assay indicates that the DharmaFECT® 1 transfection reagent was responsible 
for causing the observed non-significant reduction in cellular viability (Figure 3.7).       
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 - The effect of siRNA-scr and DharmaFECT®  1 reagent on cellular 
viability. HeLa cells were incubated with siRNA-scr, DharmaFECT® 1 reagent or 
both; 72 h later, their viability was assessed using an MTT assay. siRNA-scr treated 
cells display similar viability to control cells (incubated for 72 h in DMEM containing 
10% (v/v) FCS), while the DharmaFECT® 1 and siRNA-scr + DharmaFECT® 1 
treated cells display an 8% and 9% decrease in cellular viability, respectively, 
compared to control cells (p > 0.05).    
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3.6. Assessment of the effect of the siRNA-mediated downregulation of LRP 
expression on nuclear morphology 
 
The nuclear morphology of A549 and HeLa cells was assessed 72 h post-transfection 
with siRNA-LAMR1. Additionally, the aforementioned cell lines were incubated with 
8 mM PCA (an apoptosis inducer 171) and transfected with siRNA-scr for positive and 
negative control purposes, respectively. The cells were then stained with the 
fluorescent nuclear dye Hoechst 33324 and viewed by immunofluorescence 
microscopy (section 2.10).  
 
siRNA-LAMR1 treated A549 and HeLa cells reveal constricted nuclei, which appear 
to have lost their integrity, indicating a loss their nuclear morphology, compared to 
siRNA-scr treated cells (Figure 3.8 – white arrows). The nuclei of cells incubated 
with 8 mM PCA appear constricted; this was expected, as this compound is a known 
apoptosis inducer 171. Before transfection/incubation, the cell number was consistent; 
we therefore suggest that the toxicity of PCA was responsible for cell death, resulting 
in decreased cell numbers observed in the corresponding micrographs.  
 
3.7. Examination of the effect of the siRNA-mediated downregulation of LRP 
expression on caspase-3 activity 
 
The activity of the apoptosis-associated effector protein, caspase-3, in response to the 
siRNA-mediated downregulation of LRP expression in A549 and HeLa cells was 
assessed using a Caspase-3 activation assay (section 2.11). Additionally, the 
aforementioned cell lines were incubated with 8 mM PCA (an apoptosis inducer 
known to increase caspase-3 activity 171) and transfected with siRNA-scr for positive 
and negative control purposes, respectively.  
 
siRNA-LAMR1 treated A549 and HeLa cells reveal a significant (** p < 0.01, *** p 
< 0.001) 9% and 83% upregulation in the activity of caspase-3, respectively, 
compared to siRNA-scr treated cells (set to 100%) (Figure 3.9). The increased activity 
of caspase-3 in A549 and HeLa cells incubated with 8 mM PCA was expected since 
this compound is an inducer of apoptosis known to increase the activity of the 
aforementioned protein 171.
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Figure 3.8 – The effect of the siRNA-mediated downregulation of LRP expression on nuclear morphology. 72 h post-transfection, A549 
and HeLa cells were stained with Hoechst 33342 and viewed by immunofluorescence microscopy. siRNA-LAMR1 treated A549 and HeLa cells 
exhibit constricted nuclei and decreased nuclear integrity (indicated by the white arrows), compared to siRNA-scr treated cells (8 mM PCA used 
as positive control).   
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Figure 3.9 – The effect of the siRNA-mediated downregulation of LRP expression on caspase-3 activity. The activity of the apoptosis-
associated protein, caspase-3, in A549 and HeLa cells was analysed 72 h post-transfection. siRNA-LAMR1 treated a) A549 and b) HeLa cells 
reveal a significant (* p < 0.01, *** p < 0.001) 9% and 83% upregulation in caspase-3 activity, respectively, compared to the siRNA-scr treated 
cells (set to 100%) (8 mM PCA used as a positive control).  
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3.8. Examination of the effect of the siRNA-mediated downregulation of LRP 
expression on cellular proliferation 
 
The proliferation of A549 and HeLa cells in response to the siRNA-mediated 
downregulation of LRP expression was assessed using a BrdU Cell Proliferation 
Assay (section 2.12). Additionally, the aforementioned cells were incubated with 100 
µg/mL Doxycycline (a known inhibitor of cellular proliferation 172) and transfected 
with siRNA-scr for positive and negative control purposes, respectively. 
 
siRNA-LAMR1 treated A549 and HeLa cells revealed a non-significant (p > 0.05) 
11% and 13% reduction in cellular proliferation, respectively, compared to siRNA-scr 
treated cells (set to 100%) (Figure 3.10). The decreased level of cellular proliferation 
observed in A549 and HeLa cells incubated with 100 µg/mL Doxycycline was 
expected as this compound is a known inhibitor of the aforementioned process 172.  
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!
Figure!3.10!–!The effect of the siRNA-mediated downregulation of LRP expression on cellular proliferation. The percentage of actively 
proliferative A549 and HeLa cells was analysed 72 h post-transfection. siRNA-LAMR1 treated a) A549 and b) HeLa cells reveal a non-
significant (p > 0.05) 11% and 13% reduction in cellular proliferation, respectively, compared to siRNA-scr treated cells (set to 100%) (100 
µg/mL Doxycycline used as a positive control). 
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4. Chapter 4 – Discussion 
 
The role of the laminin receptor in cancer progression has been a topic of great 
interest for many years and has therefore been extensively investigated. Numerous 
studies have implicated cell surface LRP/LR in the progression of cancer – this 
receptor is overexpressed on the surface of a number of cancerous cell lines, giving 
them the ability to metastasise and invade surrounding tissues 131; 132. Given that 
LRP/LR is involved in a number of cellular processes and is found in numerous 
cellular locations (the cell surface 89, the cytoplasm 8; 75; 88, the perinuclear 
compartment 75; 90; 91 and the nucleus 90; 91), additional roles of this receptor in cancer 
progression have been suggested.  
 
4.1.  Cell surface LRP/LR and total LRP levels 
 
To confirm the expression of LRP/LR in A549 and HeLa cells, cell surface LRP/LR 
(Figure 3.1) and total LRP (Figure 3.2) levels was investigated using flow cytometry 
and western blotting, respectively. Flow cytometry measured the number of A549 and 
HeLa cells in the population that expressed LRP/LR on their surface, and was not 
indicative of the level of LRP/LR on the surface of these cells. A high percentage of 
A549 and HeLa cells were shown to display cell surface LRP/LR, as expected from 
previous studies 132. In addition, total LRP expression was confirmed in both A549 
and HeLa cells, and densitometric analyses of the western blot signals revealed that 
these cells express similar total levels of LRP.  
 
The 67 kDa laminin receptor is formed from the 37 kDa laminin receptor precursor 81; 
82, with the exact mechanism of this conversion currently still elusive. However, some 
studies have suggested that unglycosylated 37 kDa LRP becomes acylated at Ser2 
through the action of fatty acids; and this acylation is a critical step in the conversion 
of 37 kDa LRP to 67 kDa LR 83; 84. We detect LRP/LR on the cell surface because it 
was discovered that both 37 kDa LRP and 67 kDa LR are present in cellular plasma 
membrane fractions, albeit 67 kDa LR in lower concentrations than its 37 kDa 
isoform 89. Furthermore, the low concentration of 67 kDa LR in cellular cytoplasmic 
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extractions renders it undetectable by western blot analysis 89; we therefore detect 
only 37 kDa LRP from these extractions.     
  
4.2. LRP silencing  
 
To determine the role played by LRP/LR in the tumorigenic lung and cervical cancer 
cells, it was essential for LRP expression to be decreased. This necessitated the 
introduction of foreign nucleic acids (in a process known as transfection) into these 
cells. The foreign nucleic acids would integrate into the RNAi system, causing the 
degradation of LRP mRNA, consequently decreasing LRP expression. Since each cell 
line possesses a different level of transfectability, the transfection efficiency of the 
A549 and HeLa cells was determined. To accomplish this, these cells were 
transfected with a plasmid encoding for the green fluorescent protein (pCI-neo-GFP), 
stained with the nuclear stain Hoechst 33342 and subsequently viewed by 
immunofluorescence microscopy. The observance of both blue and green 
fluorescence (Figure 3.3) indicated that A549 and HeLa cells are both transfectable. 
Since green fluorescence was observed surrounding each nuclei for both the A549 
and HeLa cells, we concluded that their transfection efficiency was 100%. This 
finding allowed for further experimentation.      
 
A549 and HeLa cells were transfected with the pTZ57R/T shRNA-1.1 plasmid 
produced within this study, which encodes for shRNA directed against LRP mRNA, 
to possibly downregulate LRP expression. However, subsequent densitometric 
analyses of the obtained western blot signals revealed non-significant differences in 
the expression levels of LRP in the aforementioned cell lines (Figure 3.4). The same 
transfection protocol and reagent was used to introduce both the pCI-neo-GFP and the 
pTZ57R/T shRNA-1.1 plasmid DNA into the A549 and HeLa cells, and since the 
introduction of the pCI-neo-GFP plasmid was successful, the efficacy of the 
transfection method and reagent was not questioned. The ability of shRNA to 
successfully downregulate the expression of a particular protein is not only dependent 
on its ability to enter the cells, but also on its overall design, specificity and target 
sequence. The LRP target sequence for shRNA-1.1 was generated using The RNAi 
Consortium, and was chosen because of the high probability it boasted to bring about 
knockdown effects. Prof. Marco Weinberg designed the oligonucleotides with 
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emphasis placed on the efficacy of the resultant shRNA. Additionally, the sequence 
specificity of the shRNA was also investigated, and since the obtained sequence was 
identical to the target sequence, it was assumed that strong complementary binding 
between the shRNA and LRP mRNA would occur, resulting in mRNA degradation 
and hence protein downregulation. Taking all this information into account, the 
reason/s for the unsuccessful downregulation of LRP expression upon transfection of 
A549 and HeLa cells with the pTZ57R/T shRNA-1.1 plasmid remains elusive.  
  
Following the unsuccessful downregulation of LRP expression using the produced 
pTZ57R/T shRNA-1.1 plasmid, siRNA directed against LRP mRNA was purchased 
and utilised further. siRNA-LAMR1 was chosen because it targeted the open reading 
frame of the human LRP gene. LRP expression was found to be significantly 
decreased in A549 and HeLa cells 72 h post-transfection with siRNA-LAMR1, 
confirmed by densitometric analysis of the western blot signals (Figure 3.5). The level 
of LRP expression in A549 and HeLa cells was significantly (** p < 0.01) reduced 
(80% and 60%, respectively), demonstrating the efficacy of the siRNA.  
 
The reduction in the expression of 37 kDa LRP was possible since both the shRNA 
and siRNA sequences targeted 37 kDa LRP mRNA. It is not possible to use RNAi to 
reduce the expression of 67 kDa LR as it is not a direct product of transcription and 
translation, rather it is thought to be produced by the post-transcriptional modification 
of 37 kDa LRP 83; 84. However, since it is understood that the 37 kDa form is a 
precursor for the 67 kDa form 84, it could be assumed that a reduction in the 
expression of LRP would consequently reduce the expression of LR.  
 
4.3. Cellular viability 
 
The effect of the downregulation of LRP expression on the viability of cancerous cells 
(an important characteristic of the disease) was then investigated. LRP 
downregulation was found to correlate with a significant (* p < 0.05, ** p < 0.01) 
reduction in the viability of A549 and HeLa cells (Figure 3.6), indicating a crucial 
role for LRP this process. Since the maintenance of cellular viability is imperative for 
the survival and propagation of cancerous cells, the suggestion that LRP is involved 
in this process further implicates this protein in the disease. A non-significant 
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reduction in cellular viability was however also observed in siRNA-scr treated HeLa 
cells compared to non-transfected cells (Figure 3.6b) and the DharmaFECT® 1 
transfection reagent was shown to be the causative agent in this decrease (Figure 3.7). 
This finding correlates to previous research completed by Thermo Scientific into this 
topic, where it is understood that a 20% reduction in cellular viability is a successful 
non-toxic transfection (Literature Code: 00078-06-E-02-U).    
 
4.4. Apoptosis 
 
Further experiments were performed to determine if apoptosis (a form of programmed 
cell death) was induced in A549 and HeLa cells as a result of LRP downregulation, 
and hence was responsible for the observed decrease in cellular viability in these 
cells. The presence of apoptotic A549 and HeLa cells post-transfection were firstly 
identified by visible disruptions in their nuclear morphology (Figure 3.8) and 
secondly by the significant increase in the activity of the apoptosis-associated protein 
caspase-3 (Figure 3.9).  
 
Since the laminin receptor is physiologically functional in the perinuclear 
compartment 75; 90; 91 and the nucleus 90; 91, it was not surprising that the 
downregulation of this receptor had an effect on nuclear integrity. Since LRP is 
present in the nucleus, and involved in the maintenance of nuclear structures 90, it 
could be suggested that the downregulation of LRP causes nuclear instability which 
may result in the induction of apoptosis.  
 
To further demonstrate apoptosis in the aforementioned cells, the activity of caspase-3 
was investigated. Caspase-3 is an effector protein functional at the end stage of 
apoptosis, where its activation is responsible for bringing about the observable 
changes in the cell related to this form of cell death. The identification of increased 
caspase-3 activity was therefore used as a marker for apoptosis. The activity of 
caspase-3 was higher in siRNA-LAMR1 treated HeLa cells compared to siRNA-
LAMR1 treated A549 cells, indicating that the downregulation of LPR expression 
was more effective in inducing apoptosis in HeLa cells than in A549 cells. It is 
unclear whether the increased activity of caspase-3 is as a consequence of upstream 
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events, which would initiate apoptosis in the cell, or through an inhibitory interaction 
directly with LRP. Further experiments must be performed to elucidate this.    
 
Both the loss of nuclear morphology and the increased activity of apoptosis-
associated protein, caspase-3, are indicative of apoptosis, and the results of this study 
therefore are suggestive of a critical role played by the laminin receptor in the 
blockage of this form of cell death.  
 
4.5. Cellular proliferation 
 
The proliferative state of A549 and HeLa cells post-transfection were investigated to 
determine if the observed significant decrease in cellular viability could also be 
attributed to a reduction in cell division. siRNA-LAMR1 treated cells revealed a non-
significant (p > 0.05) reduction in cellular proliferation in A549 and HeLa cells (11% 
and 13%, respectively) compared to siRNA-scr treated cells (Figure 3.10). The results 
were not significant, however, if this experiment was repeated, the standard 
deviations could be reduced and significant results possibly obtained. Since LRP is 
physiologically involved in cellular proliferation, the reduction of its expression 
would cause a disruption in this process. However, from these results, it can also be 
suggested that this receptor may play a role in allowing the aberrant proliferation of 
cancerous cells.    
  
The role of LRP in the maintenance of cellular viability and the stimulation of cellular 
proliferation has been reported in previous studies 75, additionally, the induction of 
apoptosis in cancerous cells in response to LRP downregulation has also been 
demonstrated 72. This study has confirmed the role of LRP in the maintenance of 
cellular viability and the induction of apoptosis in A549 and HeLa cells. Furthermore, 
this study has revealed that the induction of apoptosis is mediated by both a loss in 
nuclear integrity and significantly increased activity of caspase-3 in these cells.  
 
4.6. Targeting LRP/LR for cancer treatment 
 
The implications of the expression of LRP in cancer progression are vast – increased 
invasion 131; 132, metastasis 131; 132 and cellular proliferation 75 as well as decreased 
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cellular viability 75 and apoptosis 72 are processes mediated by this protein. Targeting 
LRP can therefore be developed as a potential alternative therapeutic for the treatment 
of the abovementioned processes implicated in cancer progression. Additionally, 
targeting LRP for the possible treatment of the abovementioned processes have been 
achieved in a number of cancerous cell lines. This therefore suggests that an LRP 
related therapy could potentially be utilised for the treatment of numerous distinct 
cancer types. It must however be stressed that this receptor is involved in many 
physiological processes in normal cells, including cell growth, differentiation, 
movement and attachment 86, and the downregulation of LRP in these cells would 
result in undesirable homeostatic disruptions. The targeting of LRP solely to 
cancerous cells is therefore imperative for its use as a therapeutic alternative.            
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5. Chapter 5 – Conclusion and Future Work 
 
5.1.  Conclusion 
 
This study has shown that the downregulation of LRP expression in A549 and HeLa 
cells resulted in a significant decrease in cellular viability. Additionally, it was 
demonstrated that this decrease in cellular viability was mediated by the induction of 
apoptosis (identified by visualisation of the loss in their nuclear integrity as well as 
the significantly increased activity of the apoptosis-associated protein caspase-3) and 
possibly through the inhibition of cellular proliferation. This finding is illustrated in 
Figure 5.1. 
 
Figure 5.1 – Conclusion of the study. The siRNA-mediated downregulation of LRP 
expression caused a decrease in cellular viability, resultant from the induction of 
apoptosis and possibly the inhibition of cellular proliferation.  
 
The findings of this study indicate that targeting LRP mRNA could possibly be used 
as an alternative therapeutic strategy for the treatment of cancer.  
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5.2. Future Work  
 
The following experiments can be suggested from the findings of this study.  
 
Research from a number of reports has been accumulated to suggest crucial roles for 
LRP/LR in the maintenance of the viability of cancerous cells, the promotion of 
metastasis, the blockage of apoptosis and the stimulation of cellular proliferation. It 
would be interesting to determine if targeting LRP/LR with a single specific tool 
(shRNA, siRNA, antibodies etc.) could cause all the aforementioned cancer related 
processes to become disrupted.  
 
Even though it is possible that LRP/LR targeted therapies for cancer can be beneficial 
for the treatment of this disease, it also has the potential to be extremely problematic 
in non-cancerous tissues. Therefore, it would be necessary to determine the effects of 
LRP downregulation on normal tissues. Additionally, research into therapies involved 
in targeting LRP/LR exclusively on cancerous tissues is necessary – the use of viral 
delivery vectors could be successful in this endeavour.  
 
Moreover, targeting LRP/LR could be investigated in animal models using nude mice 
and if successful, the effectiveness of these therapies in humans could be further 
assessed in clinical trials.  
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Appendix  
 
1. Plasmids 
 
1.1. pCI-neo 
 
Figure A1 – pCI-neo plasmid map. 
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1.2. pti-H1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2 – pti-H1 plasmid map. 
 
1.3. pTZ57R/T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3 - pTZ57R/T plasmid map. 
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1.4. LB, LB-Amp and LB-Amp/Xgal/IPTG plates 
 
1.4.1. 20 mg/mL  Ampicillin 
 
Dissolve 0.02% (w/v) ampicillin dH20 and store in 1mL aliquots at -20 °C. 
 
1.4.2. 40 mg/mL  Xgal 
 
Dissolve 0.4% (w/v) Xgal in DMSO and store in 1 mL aliquots in foil wrapped 
eppendorf tubes at -20 °C. 
 
1.4.3. 100 mM  IPTG 
 
Dissolve 238 mg IPTG in 10 mL dH20 and store in 1 mL aliquots at -20 °C 
 
1.4.4. LB-plates  
 
Dissolve the following in dH20 
10% (w/v)   Tryptone 
5% (w/v)   Yeast extract 
0.086 M   NaCl 
15% (w/v)    Agar 
Autoclave to sterilize, cool to ∼55 °C and pour ∼10 mL into a petri dish. Allow agar 
to set (∼20 min at RT) and incubate upside down at 37 °C overnight. Store plates at 4 
°C.  
 
1.4.5. LB-Amp plates 
 
Dissolve the following in dH20 
10% (w/v)   Tryptone 
5% (w/v)   Yeast extract 
0.086 M   NaCl 
15% (w/v)    Agar 
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Autoclave to sterilise, cool to ∼55 °C. Add either 2.5 µL or 5 µL of a 20 mg/mL stock 
solution of ampicillin to make the final ratio 50 µg/mL or 100 µg/mL, respectively. 
Pour ∼10 mL into a petri dish. Allow agar to set (∼20 min at RT) and incubate upside 
down at 37 °C overnight. Store plates at 4 °C.  
 
1.4.6. LB-Amp/Xgal/IPTG plates  
 
Spread 40 µL of 40 mg/mL Xgal and 40 µL of 100 mM IPTG on pre-warmed (to RT) 
LB-Amp (50 µg/mL) plates and incubate at 37 °C for 1 h before use.  
 
1.5. LB liquid medium 
 
Combine the following in dH20 
10% (w/v)  Tryptone 
5% (w/v)  Yeast Extract  
0.1 M    NaCl 
Autoclaved to sterilise and store at 4 °C    
 
1.6. 0.1 M Calcium Chloride (CaCl2) 
    
Dissolve 1.1 g CaCl2 in 100 mL dH20 and store at 4 °C 
 
1.7. 0.1 M CaCl2 containing 15% glycerol 
 
Combine  
1.1 g   CaCl2 
15 mL   Glycerol 
Make up volume to 100 mL with dH20 and store at 4 °C 
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2. Determination of total LRP levels 
 
2.1. Lysis buffer 
 
Combine the following in dH20: 
10 mM  Tris-HCl 
100 mM  NaCl 
10 mM  EDTA 
0.5% (v/v)  Nonident-P40 
0.05% (w/v)  Deoxycholate 
Store solution at 4 °C 
 
2.2. 5 X Sample loading dye 
 
Combine the following in dH20: 
10% (w/v)  SDS 
10 mM  β-mercapto-ethanol 
20% (v/v)  Glycerol 
0.2 M   Tris-HCl (pH 6.8) (appendix 2.3.4) 
0.05%   Bromophenolblue 
Store at 4 °C (-20 °C long term)  
 
2.3. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
2.3.1. 1 X SDS running buffer 
 
Combine the following in dH20: 
0.2 M   Tris  
0.19 M  Glycine 
3 mM   SDS 
Store at RT 
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2.3.2. 40% Acrylamide:Bis-Acrylamide  
 
Combine Acrylamide and Bis-Acylamide (19:1) in dH20.  
Heat to dissolve, filter and store in dark bottles at 4 °C 
 
2.3.3. Separation buffer 
 
Combine the following in dH20: 
1.5 M   Tris  
pH to 8.8 with HCl 
Store at 4 °C 
 
2.3.4. Stacking buffer 
 
Combine the following in dH20: 
500 mM  Tris  
pH to 6.8 with HCl 
Store at 4 °C 
 
2.3.5. 10% SDS 
 
Dissolve 10% (w/v) SDS in dH20 and store at RT 
 
2.3.6. 1% APS 
 
Dissolve 1% (w/v) APS in dH20 and store at 4 °C 
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2.3.7. 12% Separating and 5% Stacking gel 
 
2.3.7.1. 12% Separating gel 
 
Combine the following in dH20: 
 
29.9% (v/v)  40% Acrylamide:Bis-Acrylamide 
25% (v/v)  Separation buffer 
1% (v/v)  10% SDS 
1% (v/v)  1% APS 
0.4% (v/v)  TEMED 
 
2.3.7.2. 5% Stacking gel 
 
Combine following in dH20: 
 
12.5% (v/v)  40% Acrylamide:Bis-Acrylamide 
12.5% (v/v)  Stacking buffer 
1% (v/v)  10% SDS 
1% (v/v)  1% APS 
0.1% (v/v)  TEMED 
 
2.3.7.3. Pouring gels 
 
Pour the 12% separation gel, overlay with ethanol until polymerised. Remove the 
ethanol, pour the 5% stacking gel and insert the comb.  
 
2.3.8. Transfer Buffer 
 
Combine the following in dH20: 
20 mM  Tris  
150 mM  Glycine 
20%   Methanol 
Store at 4 °C 
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2.4. 1 X PBS 
 
Combine the following in dH20: 
137 mM  NaCl 
12 mM  Phosphate 
2.7 mM  KCl 
pH 7.4 
Store at RT 
 
2.5. PBS-Tween 
 
Add 0.001% Tween to 1 X PBS 
Store at 4 °C 
 
2.6. 3% BSA in PBS-Tween 
 
Dissolve 3% BSA in PBS-Tween 
Store at 4 °C 
 
3. Determination of cell surface LRP/LR levels 
 
3.1. 4% paraformaldehyde 
 
Dissolve 4% paraformaldehyde in 0.1 M PBS. 
 
Heat solution at 65 °C while stirring and add 1N NaOH drop wise until the solution 
clears. Cool, filter and store solution at 4 °C 
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4. Transfection of A549 and HeLa cells with pCI-neo-GFP 
 
4.1. 2% paraformaldehyde 
 
Dissolve 2% paraformaldehyde in 0.1 M PBS. 
 
Heat at 65 °C while stirring and add 1N NaOH drop wise until the solution clears. 
Cool, filter and store solution at 4 °C 
 
4.2. 0.25% Triton X-100 containing 0.5% BSA in PBS 
 
Dissolve the following in 1 X PBS 
0.25%   Triton X-100 
0.5%   BSA 
Store at 4 °C 
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5. Production of shRNA 
 
5.1. shRNA design 
Figure A4 – Design of shRNA-1, 4 and 7 oligonucleotides. The design and target 
sequences of shRNA-1, 4 and 7. 
                         GCUCGUGCAAUUGUUGCCAUU 
 5'
                         C                         C                         U                         G                         A
                         C                         C                         C                         A                         CGAGCACGUUAACAACGGUAA                          U                         U 3’
SENSE
ANTISENSE
LOOP
LRP shRNA-1 STRUCTURE
GTATGAGACCACTCGGACCCGCTCGTGCAATTGTTGCCATTCCTGACCCAAATGGCAACAATTGCACGAGCTTTTTT
H1 PROMOTER PRIMING SENSE LOOP ANTISENSE TERM
 5'  3’
CCATTTGGGTCAGGAATGGCAACAATTGCACGAGCGGGTCCGAGTGGTCTCATAC 5'  3’
LRP shRNA-1: 5'-3': (OLIGOS TO ORDER)
LRP shRNA-1: 5'-3':
CATACTCTGGTGAGCCTGGGCGAGCACGTTAACAACGGTAAGGACTGGGTTTACCGTTGTTAACGTGCTCGAAAAAA  5’ 3’
CATACTCTGGTGAGCCTGGGCGAGCACGTTAACAACGGTAAGGACTGGGTTTACC  5’ 3’
 GTAAGGACTGGGTTTACCGTTGTTAACGTGCTCGAAAAAA 5' 3’
AAAAAAGCTCGTGCAATTGTTGCCATTTGGGTCAGGAATG 5'  3’
LRP-shRNA-1 R1
LRP-shRNA-1 R2
                         GCCAGAUCCAGGCAGCCUUCU 
 5'
                         C                         C                         U                         G                         A
                         C                         C                         C                         A                         CGGUCUAGGUCCGUCGGAAGG                          U                         U 3’
SENSE
ANTISENSE
LOOP
LRP shRNA-4 STRUCTURE
GTATGAGACCACTCGGACCCGCCAGATCCAGGCAGCCTTCTCCTGACCCAGGAAGGCTGCCTGGATCTGGCTTTTTT
H1 PROMOTER PRIMING SENSE LOOP ANTISENSE TERM
 5'  3’
CTTCCTGGGTCAGGAGAAGGCTGCCTGGATCTGGCGGGTCCGAGTGGTCTCATAC 5'  3’
LRP shRNA-4: 5'-3': (OLIGOS TO ORDER)
LRP shRNA-4: 5'-3':
CATACTCTGGTGAGCCTGGGCGGTCTAGGTCCGTCGGAAGAGGACTGGGTCCTTCCGACGGACCTAGACCGAAAAAA 5’ 3’
CATACTCTGGTGAGCCTGGGCGGTCTAGGTCCGTCGGAAGAGGACTGGGTCCTTC  5’ 3’
 AAGAGGACTGGGTCCTTCCGACGGACCTAGACCGAAAAAA 5' 3’
AAAAAAGCCAGATCCAGGCAGCCTTCCTGGGTCAGGAGAA 5'  3’
LRP-shRNA-4 R1
LRP-shRNA-4 R2
                         GGCAGUGACCAAGGAGGAAUU 
 5'
                         C                         C                         U                         G                         A
                         C                         C                         C                         A                         CCGUCACUGGUUCCUCCUUAA                          U                         U 3’
SENSE
ANTISENSE
LOOP
LRP shRNA-7 STRUCTURE
GTATGAGACCACTCGGACCC CCTGACCCA TTTTTTGGCAGTGACCAAGGAGGAATT AATTCCTCCTTGGTCACTGCC
H1 PROMOTER PRIMING SENSE LOOP ANTISENSE TERM
 5'  3’
GAATTTGGGTCAGGAATTCCTCCTTGGTCACTGCCGGGTCCGAGTGGTCTCATAC 5'  3’
LRP shRNA-7: 5'-3': (OLIGOS TO ORDER)
LRP shRNA-7: 5'-3':
CATACTCTGGTGAGCCTGGGCCGTCACTGGTTCCTCCTTAAGGACTGGGTTTAAGGAGGAACCAGTGACGGAAAAAA 5’ 3’
CATACTCTGGTGAGCCTGGGCCGTCACTGGTTCCTCCTTAAGGACTGGGTTTAAG  5’ 3’
 TTAAGGACTGGGTTTAAGGAGGAACCAGTGACGGAAAAAA 5' 3’
AAAAAAGGCAGTGACCAAGGAGGAATTTGGGTCAGGAATT 5'  3’
LRP-shRNA-7 R1
LRP-shRNA-7 R2
                         GCTCGTGCAATTGTTGCCATT 
LRP shRNA-1 TARGET
 5'  3’
                         CCAGATCCAGGCAGCCTTCC  5'  3’
LRP shRNA-4 TARGET
                         GGCAGTGACCAAGGAGGAATT  5'  3’
LRP shRNA-7 TARGET
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5.2. PCR amplification of oligonucleotides 
 
 
Figure A5 – Nested PCR amplification of oligonucleotides. a) Primary and b) 
secondary PCR products resolved on 1% agarose gels displaying 300 and 350 bp 
fragments, respectively.    
 
 
5.3. Transformation of pTZ57R/T shRNA-1, 4 and 7 plasmids and blue/white 
selection  
 
 
Figure A6 – Transformation of pTZ57R/T shRNA-1, 4 and 7 into E. coli XL1-
Blue. a) shRNA-1, b) shRNA-4 and c) shRNA-7 transformed into E. coli XL-Blue 
and plated on LB-amp, Xgal, and IPTG plates, allowing for blue/white selection.  
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5.4. 1 X TBE 
 
Combine the following in dH20: 
0.09 M Tris 
0.09 M Boric Acid 
0.003 M EDTA 
Store at RT 
 
5.5. 1% Agarose gel 
 
Dissolve 0.5 g agarose in 50 mL 1 X TBE buffer. 
Heat until the agarose has completely dissolved. 
Add GelStar™ (Lonza) in a 1:10 000 ratio, pour into gel mould, insert comb and 
allow to solidify.   
 
6. Examination of cellular viability 
 
6.1. Transfection per well (96 well plate format)  
 
0.6 X 104 A549 and 3 X 103 HeLa cells were seeded in the wells of a 96 well plate. 24 
h later, 150 µmol (for A549 cells) or 200 µmol (for HeLa cells) of siRNA-LAMR1 
and 0.2 µL of DharmaFECT® 1 transfection reagent were each concurrently diluted 
in DMEM to a final volume of 10 µL, the contents of each tube was gently mixed and 
allowed to incubate for 5 min at RT. The diluted siRNA-LAMR1 solution was then 
added to the diluted DharmaFECT® 1 transfection reagent, mixed gently and 
incubated for 20 min at RT. The culture medium was removed from the plated cells 
(either A549 or HeLa) and 80 µL DMEM containing 10% (v/v) FCS added to the 
siRNA-reagent solution which the cells were then grown in for 72 h in a humidified 
incubator at 37 °C with 95% air and 5% CO2.   
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6.2. 8 mM PCA 
 
Dissolve 8 mM PCA in DMEM containing 10% (v/v) FCS and store at 4 °C 
 
6.3. 1 mg/mL MTT 
 
Dissolve 1 mg of MTT in 1 mL PBS and store in a dark bottle at 4 °C. 
 
7. Assessment of cellular proliferation 
 
7.1. 100 µg/mL Doxycycline 
 
Dissolve 100 µg of Doxycycline in 1 mL DMEM containing 10% (v/v) FCS and store 
at 4 °C 
